https://whdc.ac/index.php?action=history&feed=atom&title=4FADB%2C4F-ADB%2C 2026-05-25T22:03:56Z Revision history for this page on the wiki MediaWiki 1.43.5 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225313&oldid=prev 2026-05-24T09:57:10Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:57, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound&lt;br&gt;&lt;br&gt;&lt;br&gt;</del>Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">These </del>synthetic cannabinoids <del style="font-weight: bold; text-decoration: none;">act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found </del>in <del style="font-weight: bold; text-decoration: none;">marijuana, but have different chemical structures unrelated to Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC, different metabolism, and often greater toxicity (Fantegrossi et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2014). Discriminative stimulus effects were tested </del>in <del style="font-weight: bold; text-decoration: none;">rats trained to discriminate Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol </del>(<del style="font-weight: bold; text-decoration: none;">3 </del>mg/kg, <del style="font-weight: bold; text-decoration: none;">30-min pretreatment</del>)<del style="font-weight: bold; text-decoration: none;">. 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA </del>(<del style="font-weight: bold; text-decoration: none;">also known as 5F-ADB</del>, <del style="font-weight: bold; text-decoration: none;">5F-ADB-PINACA</del>), <del style="font-weight: bold; text-decoration: none;">MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, </del>and <del style="font-weight: bold; text-decoration: none;">AMB-FUBINACA (also known as FUB-AMB</del>, <del style="font-weight: bold; text-decoration: none;">MMB-FUBINACA) were </del>tested <del style="font-weight: bold; text-decoration: none;">for in vivo cannabinoid</del>-<del style="font-weight: bold; text-decoration: none;">like effects to assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">All </del>of the <del style="font-weight: bold; text-decoration: none;">compounds </del>tested <del style="font-weight: bold; text-decoration: none;">in the present study depressed </del>locomotor activity <del style="font-weight: bold; text-decoration: none;">as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function </del>of <del style="font-weight: bold; text-decoration: none;">time (10 </del>min <del style="font-weight: bold; text-decoration: none;">bins) </del>and <del style="font-weight: bold; text-decoration: none;">dose. Depressant effects of 1.33 mg/kg were observed within 10 min following </del>administration <del style="font-weight: bold; text-decoration: none;">and peak depressant effects were [https://cannabinoidsrc4f-adb</del>.<del style="font-weight: bold; text-decoration: none;">com/ 5CL ADBA powder] observed between 0–30 min</del>. <del style="font-weight: bold; text-decoration: none;">Duration </del>of the <del style="font-weight: bold; text-decoration: none;">locomotor depression increased over </del>dose <del style="font-weight: bold; text-decoration: none;">from 30 min following 0.1 </del>mg/kg <del style="font-weight: bold; text-decoration: none;">to 2</del>.<del style="font-weight: bold; text-decoration: none;">5 h following 1 mg/k</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">A 30-min period, beginning when maximal depression </del>of <del style="font-weight: bold; text-decoration: none;">locomotor activity first appeared as a function of dose, was used for analysis of dose</del>-<del style="font-weight: bold; text-decoration: none;">response data and calculation of ED50 values. During test sessions</del>, <del style="font-weight: bold; text-decoration: none;">both levers were active, such </del>that <del style="font-weight: bold; text-decoration: none;">ten consecutive responses on either lever led </del>to <del style="font-weight: bold; text-decoration: none;">5CL ADBA powder reinforcement. The substitution tests occurred only if </del>the <del style="font-weight: bold; text-decoration: none;">rats had achieved 85% injection-appropriate responding on the two prior training sessions.</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">The locomotor activity assay </del>was <del style="font-weight: bold; text-decoration: none;">used </del>to <del style="font-weight: bold; text-decoration: none;">identify approximate time courses </del>and <del style="font-weight: bold; text-decoration: none;">dose ranges </del>of <del style="font-weight: bold; text-decoration: none;">psychoactive effects</del>, <del style="font-weight: bold; text-decoration: none;">which is useful for identifying parameters for drug discrimination experiments </del>and <del style="font-weight: bold; text-decoration: none;">are also predictive </del>of <del style="font-weight: bold; text-decoration: none;">the time course </del>of <del style="font-weight: bold; text-decoration: none;">the psychoactive effects in human users</del>. The <del style="font-weight: bold; text-decoration: none;">purpose of </del>the present study <del style="font-weight: bold; text-decoration: none;">was </del>to <del style="font-weight: bold; text-decoration: none;">assess the abuse liability of 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-CHIMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA, </del>and <del style="font-weight: bold; text-decoration: none;">AMB-FUBINACA</del>. <del style="font-weight: bold; text-decoration: none;">Since there </del>is <del style="font-weight: bold; text-decoration: none;">currently no robust measure of the reinforcing/rewarding effects of cannabinoids</del>, <del style="font-weight: bold; text-decoration: none;">drug discrimination is currently </del>the <del style="font-weight: bold; text-decoration: none;">best model for assessing abuse liability </del>of <del style="font-weight: bold; text-decoration: none;">cannabinoids</del>. <del style="font-weight: bold; text-decoration: none;">The findings produce an apparent paradox</del>, <del style="font-weight: bold; text-decoration: none;">since CPP </del>and <del style="font-weight: bold; text-decoration: none;">self</del>-<del style="font-weight: bold; text-decoration: none;">administration predict with high reliability the likelihood that </del>a compound <del style="font-weight: bold; text-decoration: none;">will be abused by humans</del>, and <del style="font-weight: bold; text-decoration: none;">cannabinoids are well</del>-<del style="font-weight: bold; text-decoration: none;">known to produce active drug-seeking in human</del>&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <del style="font-weight: bold; text-decoration: none;">5CL ADBA </del>powder highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.&lt;br&gt;Michael B Gat</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Such decrease remained 2 hr after the administration (Table 4). In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared to the negative control treated group. Change of body weight following the treatments with JWH-081 and JWH-210 in mic&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested </ins>synthetic cannabinoids <ins style="font-weight: bold; text-decoration: none;">showed decreased weight gain rate </ins>in <ins style="font-weight: bold; text-decoration: none;">a dose</ins>-<ins style="font-weight: bold; text-decoration: none;">dependent manner</ins>. <ins style="font-weight: bold; text-decoration: none;">A total of 5 mice </ins>in <ins style="font-weight: bold; text-decoration: none;">the JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">081 </ins>(<ins style="font-weight: bold; text-decoration: none;">5 </ins>mg/kg, <ins style="font-weight: bold; text-decoration: none;">i.p.</ins>) <ins style="font-weight: bold; text-decoration: none;">treated group and 6 mice in the JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 </ins>(<ins style="font-weight: bold; text-decoration: none;">5 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">i.p.</ins>) <ins style="font-weight: bold; text-decoration: none;">treated group showed loss of traction</ins>, <ins style="font-weight: bold; text-decoration: none;">of which 4 </ins>and <ins style="font-weight: bold; text-decoration: none;">5 showed tremor</ins>, <ins style="font-weight: bold; text-decoration: none;">respectively. Memory retention was measured after the memory acquisition was </ins>tested <ins style="font-weight: bold; text-decoration: none;">as a probe trial.&lt;br&gt;About Powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">2</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Some mice showed abnormal behaviors (catalepsy, loss of traction, convulsion) right after the administration </ins>of the tested <ins style="font-weight: bold; text-decoration: none;">substances. The </ins>locomotor activity of <ins style="font-weight: bold; text-decoration: none;">the mice was measured 30 </ins>min and <ins style="font-weight: bold; text-decoration: none;">2 hrs after the last substance </ins>administration. <ins style="font-weight: bold; text-decoration: none;">We also examined their neurotoxicity using brain samples through histopathological diagnose, especially in the nucleus accumbens core region</ins>. <ins style="font-weight: bold; text-decoration: none;">In histopathological analysis, neural cells </ins>of the <ins style="font-weight: bold; text-decoration: none;">animals treated with the high </ins>dose <ins style="font-weight: bold; text-decoration: none;">(5 </ins>mg/kg<ins style="font-weight: bold; text-decoration: none;">) of JWH-081 or JWH-210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens, suggesting neurotoxicity</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Table of Conten</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">While the patient's symptoms strongly suggest the inhalation </ins>of <ins style="font-weight: bold; text-decoration: none;">ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">BUTINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">it is worth considering </ins>that <ins style="font-weight: bold; text-decoration: none;">these symptoms could also be attributed </ins>to <ins style="font-weight: bold; text-decoration: none;">nicotine exposure, as </ins>the <ins style="font-weight: bold; text-decoration: none;">symptoms partially overlap with known nicotine effect&lt;br&gt;&lt;br&gt;</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Morris water maze test </ins>was <ins style="font-weight: bold; text-decoration: none;">performed </ins>to <ins style="font-weight: bold; text-decoration: none;">evaluate the changes in learning </ins>and <ins style="font-weight: bold; text-decoration: none;">memory function. Only a few case reports about the dangers </ins>of <ins style="font-weight: bold; text-decoration: none;">some synthetic cannabinoids due to neurotoxicity have been published (Cohen et al., 2012; McGuinness et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2012; Harris </ins>and <ins style="font-weight: bold; text-decoration: none;">Brown, 2013; Hermanns et al., 2013). In addition, the lack </ins>of <ins style="font-weight: bold; text-decoration: none;">information about neurotoxicity </ins>of <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoids could allow abusers consume those substances undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity</ins>. The <ins style="font-weight: bold; text-decoration: none;">substances used in </ins>the present study <ins style="font-weight: bold; text-decoration: none;">both possess naphthoylindole moiety as their parental structure. (B) The ratio of damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity </ins>to <ins style="font-weight: bold; text-decoration: none;">total cells were calculated in nucleus accumben&lt;br&gt;&lt;br&gt;&lt;br&gt;In summary, JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 Chemical Powder stands out as a high</ins>-<ins style="font-weight: bold; text-decoration: none;">quality research compound designed for professionals who demand accuracy</ins>, <ins style="font-weight: bold; text-decoration: none;">consistency</ins>, <ins style="font-weight: bold; text-decoration: none;">and reliability. This commitment to JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 powder quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging</ins>, <ins style="font-weight: bold; text-decoration: none;">every stage of the process is monitored to ensure compliance with laboratory</ins>-<ins style="font-weight: bold; text-decoration: none;">grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features </ins>and <ins style="font-weight: bold; text-decoration: none;">Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone</ins>. <ins style="font-weight: bold; text-decoration: none;">This compound </ins>is <ins style="font-weight: bold; text-decoration: none;">appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized</ins>, <ins style="font-weight: bold; text-decoration: none;">independently tested JWH-210 JWH-210 powder should be considered.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores </ins>the <ins style="font-weight: bold; text-decoration: none;">importance </ins>of <ins style="font-weight: bold; text-decoration: none;">responsible sourcing and strict adherence to legal frameworks</ins>. <ins style="font-weight: bold; text-decoration: none;">Forensic labs, public health researchers</ins>, and <ins style="font-weight: bold; text-decoration: none;">customs officials use authentic samples like JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 to distinguish between legal and illegal compounds in seized materials. For those seeking </ins>a <ins style="font-weight: bold; text-decoration: none;">dependable </ins>compound <ins style="font-weight: bold; text-decoration: none;">for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition</ins>, and <ins style="font-weight: bold; text-decoration: none;">secure packaging, it remains a valuable resource for laboratory</ins>-<ins style="font-weight: bold; text-decoration: none;">based researc</ins>&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb.com/ JWH-210 </ins>powder<ins style="font-weight: bold; text-decoration: none;">] </ins>highest dose tested (0.5 mg/kg).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.&lt;br&gt;Michael B Gat</div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225305&oldid=prev 2026-05-24T09:56:25Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:56, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>AMB-FUBINACA <del style="font-weight: bold; text-decoration: none;">has been implicated </del>in <del style="font-weight: bold; text-decoration: none;">severe adverse </del>effects <del style="font-weight: bold; text-decoration: none;">in recreational users </del>(<del style="font-weight: bold; text-decoration: none;">Adams </del>et al., <del style="font-weight: bold; text-decoration: none;">2017; Hamilton </del>et al., <del style="font-weight: bold; text-decoration: none;">2017</del>), <del style="font-weight: bold; text-decoration: none;">which suggests that </del>the <del style="font-weight: bold; text-decoration: none;">range </del>between <del style="font-weight: bold; text-decoration: none;">behaviorally active </del>and <del style="font-weight: bold; text-decoration: none;">toxic doses </del>of <del style="font-weight: bold; text-decoration: none;">AMB-FUBINACA is narro</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Some mice showed abnormal behaviors (catalepsy, loss of traction, convulsion) right </del>after the administration <del style="font-weight: bold; text-decoration: none;">of the tested substances</del>. <del style="font-weight: bold; text-decoration: none;">The </del>locomotor activity <del style="font-weight: bold; text-decoration: none;">of the mice was measured 30 min and </del>2 <del style="font-weight: bold; text-decoration: none;">hrs after </del>the <del style="font-weight: bold; text-decoration: none;">last substance administration</del>. <del style="font-weight: bold; text-decoration: none;">We also examined their neurotoxicity using brain samples through histopathological diagnose, especially in the nucleus accumbens core region. In histopathological analysis, neural cells </del>of the <del style="font-weight: bold; text-decoration: none;">animals treated </del>with <del style="font-weight: bold; text-decoration: none;">the high dose (5 mg/kg) of </del>JWH-081 <del style="font-weight: bold; text-decoration: none;">or </del>JWH-210 <del style="font-weight: bold; text-decoration: none;">showed distorted nuclei and nucleus membranes </del>in <del style="font-weight: bold; text-decoration: none;">the core shell of nucleus accumbens, suggesting neurotoxicity.</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Table of Conten</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Buy Jwh-210 </del>at <del style="font-weight: bold; text-decoration: none;">USA K2 INCENSE STORE </del>and <del style="font-weight: bold; text-decoration: none;">enjoy premium quality</del>, <del style="font-weight: bold; text-decoration: none;">flexible quantities</del>, and <del style="font-weight: bold; text-decoration: none;">fast</del>, <del style="font-weight: bold; text-decoration: none;">secure shipping</del>. <del style="font-weight: bold; text-decoration: none;">Fast shipping and pure product</del>-<del style="font-weight: bold; text-decoration: none;">highly recommended for anyone needing quality incense ingredients</del>.<del style="font-weight: bold; text-decoration: none;">" 🌟🌟🌟🌟🌟 You can buy jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 online in quantities of 4F </del>ADB <del style="font-weight: bold; text-decoration: none;">10g</del>, <del style="font-weight: bold; text-decoration: none;">30g</del>, <del style="font-weight: bold; text-decoration: none;">50g</del>, <del style="font-weight: bold; text-decoration: none;">100g</del>, <del style="font-weight: bold; text-decoration: none;">150g</del>, and <del style="font-weight: bold; text-decoration: none;">200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it is classified </del>as <del style="font-weight: bold; text-decoration: none;">a controlled substance</del>, <del style="font-weight: bold; text-decoration: none;">while </del>in <del style="font-weight: bold; text-decoration: none;">others, it may be legal for research or incense use. The legal status of jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 varies by country and region.</del>&lt;br&gt; <del style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Higher prices often reflect rigorous quality control rather than markup alone. This compound </del>is <del style="font-weight: bold; text-decoration: none;">appropriate only </del>for <del style="font-weight: bold; text-decoration: none;">authorized professionals conducting lawful research or analysis</del>. <del style="font-weight: bold; text-decoration: none;">For legitimate applications</del>, <del style="font-weight: bold; text-decoration: none;">only fully characterized, independently tested JWH-210 </del>[https://cannabinoidsrc4f-adb.com/ <del style="font-weight: bold; text-decoration: none;">4F ADB</del>] <del style="font-weight: bold; text-decoration: none;">should be considered</del>.&lt;br&gt; <del style="font-weight: bold; text-decoration: none;">How to Choose Powder JWH-210 </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">This dual</del>-<del style="font-weight: bold; text-decoration: none;">use nature underscores the importance </del>of <del style="font-weight: bold; text-decoration: none;">responsible sourcing </del>and <del style="font-weight: bold; text-decoration: none;">strict adherence to legal frameworks</del>. <del style="font-weight: bold; text-decoration: none;">Forensic labs</del>, <del style="font-weight: bold; text-decoration: none;">public health researchers</del>, <del style="font-weight: bold; text-decoration: none;">and customs officials use authentic samples like JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 </del>to <del style="font-weight: bold; text-decoration: none;">distinguish between legal </del>and <del style="font-weight: bold; text-decoration: none;">illegal compounds </del>in <del style="font-weight: bold; text-decoration: none;">seized materials</del>. <del style="font-weight: bold; text-decoration: none;">For those seeking a dependable compound for analytical purposes</del>, <del style="font-weight: bold; text-decoration: none;">JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Chemical Powder provides a trusted </del>and <del style="font-weight: bold; text-decoration: none;">effective solution</del>. <del style="font-weight: bold; text-decoration: none;">With its carefully controlled production process</del>, <del style="font-weight: bold; text-decoration: none;">stable composition</del>, and <del style="font-weight: bold; text-decoration: none;">secure packaging</del>, <del style="font-weight: bold; text-decoration: none;">it remains a valuable resource for laboratory</del>-<del style="font-weight: bold; text-decoration: none;">based researc</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Morris water maze test was performed to evaluate </del>the <del style="font-weight: bold; text-decoration: none;">changes in learning </del>and <del style="font-weight: bold; text-decoration: none;">memory function. Only a few case reports about the dangers of some synthetic cannabinoids due to neurotoxicity </del>have been <del style="font-weight: bold; text-decoration: none;">published </del>(<del style="font-weight: bold; text-decoration: none;">Cohen </del>et al., <del style="font-weight: bold; text-decoration: none;">2012; McGuinness et al.</del>, <del style="font-weight: bold; text-decoration: none;">2012; Harris </del>and <del style="font-weight: bold; text-decoration: none;">Brown, 2013; Hermanns </del>et al., <del style="font-weight: bold; text-decoration: none;">2013</del>). <del style="font-weight: bold; text-decoration: none;">In addition, </del>the <del style="font-weight: bold; text-decoration: none;">lack of information about neurotoxicity of </del>synthetic cannabinoids <del style="font-weight: bold; text-decoration: none;">could allow abusers consume those substances undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity. The substances used </del>in the present study <del style="font-weight: bold; text-decoration: none;">both possess naphthoylindole moiety as their parental structure</del>. <del style="font-weight: bold; text-decoration: none;">(B) The ratio </del>of <del style="font-weight: bold; text-decoration: none;">damaged cells containing pyknotic or condensed nuclei </del>and <del style="font-weight: bold; text-decoration: none;">low hematoxilin affinity to total cells </del>were <del style="font-weight: bold; text-decoration: none;">calculated </del>in <del style="font-weight: bold; text-decoration: none;">nucleus accumben&lt;br&gt;&lt;br&gt; In</del>-<del style="font-weight: bold; text-decoration: none;">vitro metabolism </del>studies <del style="font-weight: bold; text-decoration: none;">are generally used to complement </del>these <del style="font-weight: bold; text-decoration: none;">data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) </del>have <del style="font-weight: bold; text-decoration: none;">been frequently used </del>to <del style="font-weight: bold; text-decoration: none;">elucidate metabolism of SCBs [12,13,14,15,16</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Due to </del>the <del style="font-weight: bold; text-decoration: none;">unknown toxicity of newly emerging SCRAs</del>, <del style="font-weight: bold; text-decoration: none;">forensic assessments of cases involving these substances are challenging. According to the reported cases </del>and <del style="font-weight: bold; text-decoration: none;">reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs</del>. <del style="font-weight: bold; text-decoration: none;">The concentration of 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA </del>in the <del style="font-weight: bold; text-decoration: none;">postmortem blood was 2.50 and 2.34 ng/mL</del>, and <del style="font-weight: bold; text-decoration: none;">blood alcohol concentration </del>was 2.<del style="font-weight: bold; text-decoration: none;">11 and 2</del>.<del style="font-weight: bold; text-decoration: none;">49 g</del>/<del style="font-weight: bold; text-decoration: none;">L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol</del>.&lt;br&gt; <del style="font-weight: bold; text-decoration: none;">Fig. 2</del>. &lt;br&gt;<del style="font-weight: bold; text-decoration: none;">The precursor ion m/z 396 </del>(<del style="font-weight: bold; text-decoration: none;">B10</del>, <del style="font-weight: bold; text-decoration: none;">B12/B15</del>) <del style="font-weight: bold; text-decoration: none;">was 32 Da higher than </del>the <del style="font-weight: bold; text-decoration: none;">parent drug</del>, <del style="font-weight: bold; text-decoration: none;">4F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">BINACA</del>, <del style="font-weight: bold; text-decoration: none;">suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according </del>to <del style="font-weight: bold; text-decoration: none;">their precursor ions</del>, <del style="font-weight: bold; text-decoration: none;">product ions, and fragmentation patterns </del>(<del style="font-weight: bold; text-decoration: none;">Fig</del>. <del style="font-weight: bold; text-decoration: none;">1</del>). <del style="font-weight: bold; text-decoration: none;">Traditional in-vivo metabolism studies to generate human metabolites </del>of <del style="font-weight: bold; text-decoration: none;">drugs relied heavily on </del>the <del style="font-weight: bold; text-decoration: none;">use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight </del>in-<del style="font-weight: bold; text-decoration: none;">vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation</del>, <del style="font-weight: bold; text-decoration: none;">N</del>-<del style="font-weight: bold; text-decoration: none;">dealkylation</del>, <del style="font-weight: bold; text-decoration: none;">monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.&lt;br&gt; Fig. 1. &lt;br&gt;Monitoring metabolism of synthetic cannabinoid 4F-</del>MDMB-<del style="font-weight: bold; text-decoration: none;">BINACA via high</del>-<del style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus</del>, <del style="font-weight: bold; text-decoration: none;">4F ADB liver microsomes </del>and <del style="font-weight: bold; text-decoration: none;">confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated </del>as <del style="font-weight: bold; text-decoration: none;">a little ng/mL </del>(<del style="font-weight: bold; text-decoration: none;">0</del>.<del style="font-weight: bold; text-decoration: none;">37–4</del>.<del style="font-weight: bold; text-decoration: none;">1 ng/mL according to the reported cases</del>) <del style="font-weight: bold; text-decoration: none;">of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol</del>, <del style="font-weight: bold; text-decoration: none;">because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi</del>-<del style="font-weight: bold; text-decoration: none;">organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between </del>THC <del style="font-weight: bold; text-decoration: none;">and ethanol at low or moderate ethanol doses [29</del>, <del style="font-weight: bold; text-decoration: none;">30], but no data on high doses of ethanol are available</del>. <del style="font-weight: bold; text-decoration: none;">Given that THC and ethanol act on </del>the <del style="font-weight: bold; text-decoration: none;">same receptors</del>, <del style="font-weight: bold; text-decoration: none;">data on their simultaneous use may yield important insights in this regard.&lt;br&gt; Fungus C. elegans &lt;br&gt;Concentrations of 4F-MDMB-BINACA in </del>the <del style="font-weight: bold; text-decoration: none;">postmortem blood samples were 2</del>.<del style="font-weight: bold; text-decoration: none;">50 and 2.34 ng</del>/<del style="font-weight: bold; text-decoration: none;">mL</del>, which <del style="font-weight: bold; text-decoration: none;">are in line with published data. Although the lethal dose of 4F-MDMB-BINACA </del>is <del style="font-weight: bold; text-decoration: none;">unknown, its concentration in postmortem blood samples was found to range between 0.</del>10 <del style="font-weight: bold; text-decoration: none;">and 2.90 ng/mL . In SCRA</del>-<del style="font-weight: bold; text-decoration: none;">related cases in which </del>the <del style="font-weight: bold; text-decoration: none;">deceased suffered from heart disease, the SCRA concentration </del>in the <del style="font-weight: bold; text-decoration: none;">postmortem blood was less than 1 ng/mL </del>. <del style="font-weight: bold; text-decoration: none;">Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Tremors were observed in mice 30 minutes following 1 mg/kg </ins>AMB-FUBINACA in <ins style="font-weight: bold; text-decoration: none;">the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus </ins>effects <ins style="font-weight: bold; text-decoration: none;">of early compounds was 0.81±0.17 mg/kg </ins>(<ins style="font-weight: bold; text-decoration: none;">Gatch </ins>et al., <ins style="font-weight: bold; text-decoration: none;">2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch </ins>et al., <ins style="font-weight: bold; text-decoration: none;">2018</ins>), <ins style="font-weight: bold; text-decoration: none;">and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using </ins>the <ins style="font-weight: bold; text-decoration: none;">8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action </ins>between <ins style="font-weight: bold; text-decoration: none;">1–2 h, </ins>and <ins style="font-weight: bold; text-decoration: none;">others lasting more than 2 h. There seems to be a trend </ins>of <ins style="font-weight: bold; text-decoration: none;">newer synthetic cannabinoids being more potent than earlier compound</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Such decrease remained 2 hr </ins>after the administration <ins style="font-weight: bold; text-decoration: none;">(Table 4)</ins>. <ins style="font-weight: bold; text-decoration: none;">In </ins>locomotor activity<ins style="font-weight: bold; text-decoration: none;">, methamphetamine treated group showed approximately 4.</ins>2 <ins style="font-weight: bold; text-decoration: none;">times increase compared to </ins>the <ins style="font-weight: bold; text-decoration: none;">negative control treated group</ins>. <ins style="font-weight: bold; text-decoration: none;">Change </ins>of <ins style="font-weight: bold; text-decoration: none;">body weight following </ins>the <ins style="font-weight: bold; text-decoration: none;">treatments </ins>with JWH-081 <ins style="font-weight: bold; text-decoration: none;">and </ins>JWH-210 in <ins style="font-weight: bold; text-decoration: none;">mic</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">These synthetic cannabinoids act directly </ins>at <ins style="font-weight: bold; text-decoration: none;">cannabinoid CB1 </ins>and <ins style="font-weight: bold; text-decoration: none;">CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC</ins>, <ins style="font-weight: bold; text-decoration: none;">different metabolism</ins>, and <ins style="font-weight: bold; text-decoration: none;">often greater toxicity (Fantegrossi et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2014)</ins>. <ins style="font-weight: bold; text-decoration: none;">Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30</ins>-<ins style="font-weight: bold; text-decoration: none;">min pretreatment)</ins>. <ins style="font-weight: bold; text-decoration: none;">5F-MDMB-PINACA (also known as 5F</ins>-ADB, <ins style="font-weight: bold; text-decoration: none;">5F-ADB-PINACA)</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB-CHIMICA</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">ADB-FUBINACA</ins>, and <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA (also known </ins>as <ins style="font-weight: bold; text-decoration: none;">FUB-AMB</ins>, <ins style="font-weight: bold; text-decoration: none;">MMB-FUBINACA) were tested for </ins>in <ins style="font-weight: bold; text-decoration: none;">vivo cannabinoid</ins>-<ins style="font-weight: bold; text-decoration: none;">like effects to assess their abuse liabilit&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">All of the compounds tested in the present study depressed locomotor activity as </ins>is <ins style="font-weight: bold; text-decoration: none;">typical </ins>for <ins style="font-weight: bold; text-decoration: none;">other synthetic cannabinoids (see review by Wiley et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were </ins>[https://cannabinoidsrc4f-adb.com/ <ins style="font-weight: bold; text-decoration: none;">5CL ADBA powder</ins>] <ins style="font-weight: bold; text-decoration: none;">observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 h following 1 mg/k&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">A 30</ins>-<ins style="font-weight: bold; text-decoration: none;">min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis </ins>of <ins style="font-weight: bold; text-decoration: none;">dose-response data </ins>and <ins style="font-weight: bold; text-decoration: none;">calculation of ED50 values</ins>. <ins style="font-weight: bold; text-decoration: none;">During test sessions</ins>, <ins style="font-weight: bold; text-decoration: none;">both levers were active</ins>, <ins style="font-weight: bold; text-decoration: none;">such that ten consecutive responses on either lever led to 5CL ADBA powder reinforcement. The substitution tests occurred only if the rats had achieved 85% injection</ins>-<ins style="font-weight: bold; text-decoration: none;">appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used </ins>to <ins style="font-weight: bold; text-decoration: none;">identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments </ins>and <ins style="font-weight: bold; text-decoration: none;">are also predictive of the time course of the psychoactive effects </ins>in <ins style="font-weight: bold; text-decoration: none;">human users</ins>. <ins style="font-weight: bold; text-decoration: none;">The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, </ins>and <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA</ins>. <ins style="font-weight: bold; text-decoration: none;">Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids</ins>, <ins style="font-weight: bold; text-decoration: none;">drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox</ins>, <ins style="font-weight: bold; text-decoration: none;">since CPP </ins>and <ins style="font-weight: bold; text-decoration: none;">self-administration predict with high reliability the likelihood that a compound will be abused by humans</ins>, <ins style="font-weight: bold; text-decoration: none;">and cannabinoids are well-known to produce active drug</ins>-<ins style="font-weight: bold; text-decoration: none;">seeking in human</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">4. Drugs </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">In general, </ins>the <ins style="font-weight: bold; text-decoration: none;">locomotor depressant </ins>and <ins style="font-weight: bold; text-decoration: none;">discriminative stimulus effects </ins>have been <ins style="font-weight: bold; text-decoration: none;">observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 </ins>(<ins style="font-weight: bold; text-decoration: none;">Gatch </ins>et al., <ins style="font-weight: bold; text-decoration: none;">2016)</ins>, and <ins style="font-weight: bold; text-decoration: none;">5F-AMB produced sustained vocalization and convulsions in rats (Gatch </ins>et al., <ins style="font-weight: bold; text-decoration: none;">2018</ins>). <ins style="font-weight: bold; text-decoration: none;">All of </ins>the synthetic cannabinoids <ins style="font-weight: bold; text-decoration: none;">tested </ins>in the present study <ins style="font-weight: bold; text-decoration: none;">fully substituted for the discriminative stimulus effects of Δ9-THC</ins>. <ins style="font-weight: bold; text-decoration: none;">Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period </ins>of <ins style="font-weight: bold; text-decoration: none;">maximal effect, </ins>and <ins style="font-weight: bold; text-decoration: none;">planned comparisons </ins>were <ins style="font-weight: bold; text-decoration: none;">conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity </ins>in <ins style="font-weight: bold; text-decoration: none;">mice was tested to screen for locomotor depressant effects and to identify behaviorally</ins>-<ins style="font-weight: bold; text-decoration: none;">active dose ranges and times of peak effect. Previous </ins>studies <ins style="font-weight: bold; text-decoration: none;">have demonstrated that </ins>these <ins style="font-weight: bold; text-decoration: none;">compounds </ins>have <ins style="font-weight: bold; text-decoration: none;">chemical structures similar to synthetic cannabinoids known </ins>to <ins style="font-weight: bold; text-decoration: none;">have substantial abuse liability and act at the CB1 receptor.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Michael B Gatch </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within </ins>the <ins style="font-weight: bold; text-decoration: none;">first 10 min</ins>, and <ins style="font-weight: bold; text-decoration: none;">maximal depression was observed between 0–30 min following administration</ins>. <ins style="font-weight: bold; text-decoration: none;">Tremors were observed 30 minutes following 1 mg/kg AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA </ins>in <ins style="font-weight: bold; text-decoration: none;">3 of 8 mice (data not shown). Substantial depressant effects were observed within </ins>the <ins style="font-weight: bold; text-decoration: none;">first 10 min</ins>, and <ins style="font-weight: bold; text-decoration: none;">maximal depression </ins>was <ins style="font-weight: bold; text-decoration: none;">observed between 10–40 min and lasted up to </ins>2.<ins style="font-weight: bold; text-decoration: none;">5 to 3 h at the 5CL ADBA powder highest dose tested (0</ins>.<ins style="font-weight: bold; text-decoration: none;">5 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg)</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Figure 1</ins>. &lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </ins>(<ins style="font-weight: bold; text-decoration: none;">Wiley et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2016</ins>)<ins style="font-weight: bold; text-decoration: none;">, and a compound from </ins>the <ins style="font-weight: bold; text-decoration: none;">present study</ins>, <ins style="font-weight: bold; text-decoration: none;">5F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">PINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">was found </ins>to <ins style="font-weight: bold; text-decoration: none;">activate midbrain dopamine neurons</ins>, <ins style="font-weight: bold; text-decoration: none;">but not serotonin neurons </ins>(<ins style="font-weight: bold; text-decoration: none;">Asaoka et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2016</ins>). <ins style="font-weight: bold; text-decoration: none;">As previously mentioned, all </ins>of the <ins style="font-weight: bold; text-decoration: none;">compounds tested </ins>in <ins style="font-weight: bold; text-decoration: none;">the present study (MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">PINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">CHMICA</ins>, MDMB-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA</ins>, and <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA) act </ins>as <ins style="font-weight: bold; text-decoration: none;">agonists at CB1 receptors </ins>(<ins style="font-weight: bold; text-decoration: none;">Banister et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2015, 2016; Gamage et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2018</ins>), <ins style="font-weight: bold; text-decoration: none;">which suggests these compounds will produce Δ9</ins>-THC<ins style="font-weight: bold; text-decoration: none;">-like effects</ins>, <ins style="font-weight: bold; text-decoration: none;">including abuse liability</ins>. <ins style="font-weight: bold; text-decoration: none;">Tremors were not observed following AMB-FUBINACA during </ins>the <ins style="font-weight: bold; text-decoration: none;">drug discrimination study</ins>, <ins style="font-weight: bold; text-decoration: none;">but </ins>the <ins style="font-weight: bold; text-decoration: none;">maximum dose tested was only 0</ins>.<ins style="font-weight: bold; text-decoration: none;">1 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg</ins>, which is 10-<ins style="font-weight: bold; text-decoration: none;">fold lower than </ins>the <ins style="font-weight: bold; text-decoration: none;">dose that produced tremors </ins>in the <ins style="font-weight: bold; text-decoration: none;">mice</ins>.<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt;Michael B Gat</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225272&oldid=prev 2026-05-24T09:52:55Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:52, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">A 30</del>-<del style="font-weight: bold; text-decoration: none;">min period</del>, <del style="font-weight: bold; text-decoration: none;">beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values</del>. <del style="font-weight: bold; text-decoration: none;">During test sessions</del>, <del style="font-weight: bold; text-decoration: none;">both levers were active</del>, <del style="font-weight: bold; text-decoration: none;">such </del>that <del style="font-weight: bold; text-decoration: none;">ten consecutive responses on either lever led to 5CLADBA reinforcement. The substitution tests occurred only if </del>the <del style="font-weight: bold; text-decoration: none;">rats had achieved 85% injection</del>-<del style="font-weight: bold; text-decoration: none;">appropriate responding on the two prior training sessions.</del>&lt;br&gt;The locomotor activity <del style="font-weight: bold; text-decoration: none;">assay </del>was <del style="font-weight: bold; text-decoration: none;">used to identify approximate time courses </del>and <del style="font-weight: bold; text-decoration: none;">dose ranges of psychoactive effects</del>, <del style="font-weight: bold; text-decoration: none;">which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of </del>the <del style="font-weight: bold; text-decoration: none;">psychoactive effects in human users</del>. <del style="font-weight: bold; text-decoration: none;">The purpose </del>of the <del style="font-weight: bold; text-decoration: none;">present study was to assess </del>the <del style="font-weight: bold; text-decoration: none;">abuse liability </del>of <del style="font-weight: bold; text-decoration: none;">5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">CHIMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB-FUBINACA</del>, and <del style="font-weight: bold; text-decoration: none;">AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA</del>. <del style="font-weight: bold; text-decoration: none;">Since there is currently no robust measure </del>of <del style="font-weight: bold; text-decoration: none;">the reinforcing/rewarding effects of cannabinoids</del>, <del style="font-weight: bold; text-decoration: none;">drug discrimination </del>is <del style="font-weight: bold; text-decoration: none;">currently the best model </del>for <del style="font-weight: bold; text-decoration: none;">assessing abuse liability of cannabinoids</del>. The <del style="font-weight: bold; text-decoration: none;">findings produce an apparent paradox, since CPP and self</del>-<del style="font-weight: bold; text-decoration: none;">administration predict with high reliability the likelihood that a compound will be abused </del>by <del style="font-weight: bold; text-decoration: none;">humans, </del>and <del style="font-weight: bold; text-decoration: none;">cannabinoids are well-known </del>to <del style="font-weight: bold; text-decoration: none;">produce active drug-seeking in human</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">After </del>the <del style="font-weight: bold; text-decoration: none;">incubation</del>, <del style="font-weight: bold; text-decoration: none;">mixture was centrifuged (18</del>,<del style="font-weight: bold; text-decoration: none;">000 x g</del>, <del style="font-weight: bold; text-decoration: none;">20 °C) for 5 min </del>and <del style="font-weight: bold; text-decoration: none;">0</del>.<del style="font-weight: bold; text-decoration: none;">5 μL of the supernatant </del>was <del style="font-weight: bold; text-decoration: none;">directly injected </del>to the <del style="font-weight: bold; text-decoration: none;">chromatographic system</del>. <del style="font-weight: bold; text-decoration: none;">In </del>the <del style="font-weight: bold; text-decoration: none;">next step</del>, <del style="font-weight: bold; text-decoration: none;">ammonium formate as salting agent was added to the mixture </del>and <del style="font-weight: bold; text-decoration: none;">incubated in a thermomixer (20 °C</del>, <del style="font-weight: bold; text-decoration: none;">1200 rpm</del>) <del style="font-weight: bold; text-decoration: none;">for 15 min</del>. <del style="font-weight: bold; text-decoration: none;">After vortex-mixing</del>, the <del style="font-weight: bold; text-decoration: none;">mixture was allowed to stand 5CLADBA at room temperature for 5 min</del>. <del style="font-weight: bold; text-decoration: none;">MS/MS experiments were performed </del>in <del style="font-weight: bold; text-decoration: none;">MRM </del>(<del style="font-weight: bold; text-decoration: none;">multiple reaction monitoring</del>) <del style="font-weight: bold; text-decoration: none;">mode with an isolation window </del>of <del style="font-weight: bold; text-decoration: none;">0.4 m/z. The MS measurement was performed </del>in <del style="font-weight: bold; text-decoration: none;">positive ion mode (except for some acidic compounds such as barbiturates</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Product ions detected at m/z 302, 217</del>, and <del style="font-weight: bold; text-decoration: none;">145 </del>(<del style="font-weight: bold; text-decoration: none;">B2</del>) <del style="font-weight: bold; text-decoration: none;">confirmed that tert-leucine and indazole moieties remained unchanged</del>, <del style="font-weight: bold; text-decoration: none;">leading </del>to the <del style="font-weight: bold; text-decoration: none;">structure elucidation </del>of <del style="font-weight: bold; text-decoration: none;">a hydroxy-functional group at the 4-position </del>of the <del style="font-weight: bold; text-decoration: none;">butyl side chain by oxidative defluorination. The product ion m/z 336 (loss </del>of <del style="font-weight: bold; text-decoration: none;">methyl ester moiety) further confirmed </del>the <del style="font-weight: bold; text-decoration: none;">presence of dihydroxylated metabolites. The precursor ion</del>, <del style="font-weight: bold; text-decoration: none;">m/z 364 (B14, B5/B6) had a loss </del>of <del style="font-weight: bold; text-decoration: none;">2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</del>. The <del style="font-weight: bold; text-decoration: none;">presence </del>of <del style="font-weight: bold; text-decoration: none;">the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert</del>-<del style="font-weight: bold; text-decoration: none;">leucine </del>in <del style="font-weight: bold; text-decoration: none;">B8 (m</del>/<del style="font-weight: bold; text-decoration: none;">z 219)</del>, <del style="font-weight: bold; text-decoration: none;">butyl side chain in B9 (m/z 145) </del>and <del style="font-weight: bold; text-decoration: none;">indazole moiety in B13 (m</del>/<del style="font-weight: bold; text-decoration: none;">z 161)</del>. <del style="font-weight: bold; text-decoration: none;">The precursor ion, m/z 350 showed a loss </del>of <del style="font-weight: bold; text-decoration: none;">14 Da explaining the hydrolysis of methyl ester from </del>4F-MDMB-BINACA.&lt;br&gt;Fig. 2. &lt;br&gt;<del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA </del>was <del style="font-weight: bold; text-decoration: none;">hydrolysed via ester hydrolysis forming </del>the 4F-MDMB-BINACA <del style="font-weight: bold; text-decoration: none;">ester hydrolysis metabolite (B22)</del>. <del style="font-weight: bold; text-decoration: none;">Data obtained from </del>the <del style="font-weight: bold; text-decoration: none;">twenty urine samples were retrospectively analysed and processed using TraceFinder software </del>based on the <del style="font-weight: bold; text-decoration: none;">identification criteria of mass errors less than ± 5 ppm for full MS peaks </del>and <del style="font-weight: bold; text-decoration: none;">MS/MS peaks from the theoretical mass and matching of MS/MS spectra</del>. <del style="font-weight: bold; text-decoration: none;">The mixture was vortex</del>-<del style="font-weight: bold; text-decoration: none;">mixed and 500 µL </del>of <del style="font-weight: bold; text-decoration: none;">this mixture and 500 µL </del>of <del style="font-weight: bold; text-decoration: none;">methanol were loaded onto the Clean Screen FASt® tube. After incubation</del>, <del style="font-weight: bold; text-decoration: none;">the mixture was cooled at room temperature</del>, and <del style="font-weight: bold; text-decoration: none;">150 µL of purified water was added</del>. <del style="font-weight: bold; text-decoration: none;">High</del>-<del style="font-weight: bold; text-decoration: none;">resolution QTOF-MS data </del>were <del style="font-weight: bold; text-decoration: none;">acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped </del>with <del style="font-weight: bold; text-decoration: none;">dual electrospray ionization (ESI) source operated in both positive and negative ion modes</del>, <del style="font-weight: bold; text-decoration: none;">to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC</del>-<del style="font-weight: bold; text-decoration: none;">C18 analytical column (2.7 μm</del>, <del style="font-weight: bold; text-decoration: none;">75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA)</del>.&lt;br&gt;Fig. 1. &lt;br&gt;<del style="font-weight: bold; text-decoration: none;">This outcome was anticipated since CES</del>-<del style="font-weight: bold; text-decoration: none;">mediated hydrolysis is commonly [https:</del>//<del style="font-weight: bold; text-decoration: none;">cannabinoidsrc4f-adb</del>.<del style="font-weight: bold; text-decoration: none;">com</del>/ <del style="font-weight: bold; text-decoration: none;">5CLADBA] </del>reported <del style="font-weight: bold; text-decoration: none;">as </del>the <del style="font-weight: bold; text-decoration: none;">major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides </del>and <del style="font-weight: bold; text-decoration: none;">sulfate metabolites have been reported with other SCBs where C. From these three samples</del>, <del style="font-weight: bold; text-decoration: none;">sample 2 contained only an ester hydrolysis metabolite (m/z 350)</del>. <del style="font-weight: bold; text-decoration: none;">Both ester hydrolysis followed by oxidative defluorination </del>to <del style="font-weight: bold; text-decoration: none;">butanoic acid (B4, m/z 362) </del>and <del style="font-weight: bold; text-decoration: none;">monohydroxylation at tert</del>-<del style="font-weight: bold; text-decoration: none;">leucine moiety (B8, m/z 366) metabolites were </del>found <del style="font-weight: bold; text-decoration: none;">in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected </del>at <del style="font-weight: bold; text-decoration: none;">m/z 235</del>, <del style="font-weight: bold; text-decoration: none;">indicating loss of sulfate</del>, <del style="font-weight: bold; text-decoration: none;">confirmed the identity </del>of the <del style="font-weight: bold; text-decoration: none;">sulfation metabolite</del>.&lt;br&gt;Fungus C. elegans &lt;br&gt;Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA has been implicated in severe adverse effects in recreational users (Adams et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2017; Hamilton et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2017)</ins>, <ins style="font-weight: bold; text-decoration: none;">which suggests </ins>that the <ins style="font-weight: bold; text-decoration: none;">range between behaviorally active and toxic doses of AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA is narro&lt;br&gt;&lt;br&gt;</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Some mice showed abnormal behaviors (catalepsy, loss of traction, convulsion) right after the administration of the tested substances. </ins>The locomotor activity <ins style="font-weight: bold; text-decoration: none;">of the mice </ins>was <ins style="font-weight: bold; text-decoration: none;">measured 30 min </ins>and <ins style="font-weight: bold; text-decoration: none;">2 hrs after the last substance administration. We also examined their neurotoxicity using brain samples through histopathological diagnose</ins>, <ins style="font-weight: bold; text-decoration: none;">especially in </ins>the <ins style="font-weight: bold; text-decoration: none;">nucleus accumbens core region</ins>. <ins style="font-weight: bold; text-decoration: none;">In histopathological analysis, neural cells </ins>of the <ins style="font-weight: bold; text-decoration: none;">animals treated with </ins>the <ins style="font-weight: bold; text-decoration: none;">high dose (5 mg/kg) </ins>of <ins style="font-weight: bold; text-decoration: none;">JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">081 or JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens</ins>, <ins style="font-weight: bold; text-decoration: none;">suggesting neurotoxicity.&lt;br&gt;Table of Conten&lt;br&gt;&lt;br&gt;&lt;br&gt;Buy Jwh</ins>-<ins style="font-weight: bold; text-decoration: none;">210 at USA K2 INCENSE STORE and enjoy premium quality</ins>, <ins style="font-weight: bold; text-decoration: none;">flexible quantities</ins>, <ins style="font-weight: bold; text-decoration: none;">and fast</ins>, <ins style="font-weight: bold; text-decoration: none;">secure shipping. Fast shipping </ins>and <ins style="font-weight: bold; text-decoration: none;">pure product</ins>-<ins style="font-weight: bold; text-decoration: none;">highly recommended for anyone needing quality incense ingredients</ins>.<ins style="font-weight: bold; text-decoration: none;">" 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities </ins>of <ins style="font-weight: bold; text-decoration: none;">4F ADB 10g, 30g, 50g, 100g, 150g, and 200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas</ins>, <ins style="font-weight: bold; text-decoration: none;">it </ins>is <ins style="font-weight: bold; text-decoration: none;">classified as a controlled substance, while in others, it may be legal </ins>for <ins style="font-weight: bold; text-decoration: none;">research or incense use</ins>. The <ins style="font-weight: bold; text-decoration: none;">legal status of jwh</ins>-<ins style="font-weight: bold; text-decoration: none;">210 varies </ins>by <ins style="font-weight: bold; text-decoration: none;">country and region.&lt;br&gt; Key Features </ins>and <ins style="font-weight: bold; text-decoration: none;">Specifications </ins>to <ins style="font-weight: bold; text-decoration: none;">Evaluate </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 [https://cannabinoidsrc4f-adb.com/ 4F ADB] should be considered.</ins>&lt;br&gt; <ins style="font-weight: bold; text-decoration: none;">How to Choose Powder JWH-210 </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">This dual-use nature underscores </ins>the <ins style="font-weight: bold; text-decoration: none;">importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs</ins>, <ins style="font-weight: bold; text-decoration: none;">public health researchers</ins>, <ins style="font-weight: bold; text-decoration: none;">and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes</ins>, <ins style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder provides a trusted </ins>and <ins style="font-weight: bold; text-decoration: none;">effective solution</ins>. <ins style="font-weight: bold; text-decoration: none;">With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based researc&lt;br&gt;&lt;br&gt;&lt;br&gt;Morris water maze test </ins>was <ins style="font-weight: bold; text-decoration: none;">performed </ins>to <ins style="font-weight: bold; text-decoration: none;">evaluate </ins>the <ins style="font-weight: bold; text-decoration: none;">changes in learning and memory function</ins>. <ins style="font-weight: bold; text-decoration: none;">Only a few case reports about </ins>the <ins style="font-weight: bold; text-decoration: none;">dangers of some synthetic cannabinoids due to neurotoxicity have been published (Cohen et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2012; McGuinness et al., 2012; Harris </ins>and <ins style="font-weight: bold; text-decoration: none;">Brown, 2013; Hermanns et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2013</ins>). <ins style="font-weight: bold; text-decoration: none;">In addition</ins>, the <ins style="font-weight: bold; text-decoration: none;">lack of information about neurotoxicity of synthetic cannabinoids could allow abusers consume those substances undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity</ins>. <ins style="font-weight: bold; text-decoration: none;">The substances used </ins>in <ins style="font-weight: bold; text-decoration: none;">the present study both possess naphthoylindole moiety as their parental structure. </ins>(<ins style="font-weight: bold; text-decoration: none;">B</ins>) <ins style="font-weight: bold; text-decoration: none;">The ratio </ins>of <ins style="font-weight: bold; text-decoration: none;">damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity to total cells were calculated </ins>in <ins style="font-weight: bold; text-decoration: none;">nucleus accumben</ins>&lt;br&gt;&lt;br&gt; <ins style="font-weight: bold; text-decoration: none;">In-vitro metabolism studies are generally used to complement these data using perfused organs</ins>, <ins style="font-weight: bold; text-decoration: none;">tissue or cell cultures </ins>and <ins style="font-weight: bold; text-decoration: none;">microsomal preparations amongst which pooled human liver microsomes </ins>(<ins style="font-weight: bold; text-decoration: none;">HLM</ins>) <ins style="font-weight: bold; text-decoration: none;">have been frequently used to elucidate metabolism of SCBs [12,13,14,15</ins>,<ins style="font-weight: bold; text-decoration: none;">16&lt;br&gt;&lt;br&gt;&lt;br&gt;Due </ins>to the <ins style="font-weight: bold; text-decoration: none;">unknown toxicity </ins>of <ins style="font-weight: bold; text-decoration: none;">newly emerging SCRAs, forensic assessments </ins>of <ins style="font-weight: bold; text-decoration: none;">cases involving these substances are challenging. According to </ins>the <ins style="font-weight: bold; text-decoration: none;">reported cases and reviews </ins>of the <ins style="font-weight: bold; text-decoration: none;">scientific literature</ins>, <ins style="font-weight: bold; text-decoration: none;">concurrent ethanol consumption should amplify the toxicity </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRAs</ins>. The <ins style="font-weight: bold; text-decoration: none;">concentration </ins>of <ins style="font-weight: bold; text-decoration: none;">4F-MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA </ins>in <ins style="font-weight: bold; text-decoration: none;">the postmortem blood was 2.50 and 2.34 ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL</ins>, and <ins style="font-weight: bold; text-decoration: none;">blood alcohol concentration was 2.11 and 2.49 g</ins>/<ins style="font-weight: bold; text-decoration: none;">L, respectively</ins>. <ins style="font-weight: bold; text-decoration: none;">Two fatal cases are reported caused by simultaneous consumption </ins>of 4F-MDMB-BINACA <ins style="font-weight: bold; text-decoration: none;">and ethanol</ins>.&lt;br&gt; Fig. 2. &lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">The precursor ion m/z 396 (B10, B12/B15) </ins>was <ins style="font-weight: bold; text-decoration: none;">32 Da higher than </ins>the <ins style="font-weight: bold; text-decoration: none;">parent drug, </ins>4F-MDMB-BINACA<ins style="font-weight: bold; text-decoration: none;">, suggesting the addition of two hydroxy groups</ins>. <ins style="font-weight: bold; text-decoration: none;">All </ins>the <ins style="font-weight: bold; text-decoration: none;">below explanations for transformations into metabolites are </ins>based on the <ins style="font-weight: bold; text-decoration: none;">data shown in Fig. Metabolites were identified according to their precursor ions, product ions, </ins>and <ins style="font-weight: bold; text-decoration: none;">fragmentation patterns (Fig. 1)</ins>. <ins style="font-weight: bold; text-decoration: none;">Traditional in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolism studies to generate human metabolites </ins>of <ins style="font-weight: bold; text-decoration: none;">drugs relied heavily on the use </ins>of <ins style="font-weight: bold; text-decoration: none;">whole animal model systems, which are expensive</ins>, <ins style="font-weight: bold; text-decoration: none;">limited by drug administration amount</ins>, <ins style="font-weight: bold; text-decoration: none;">influenced by species variation </ins>and <ins style="font-weight: bold; text-decoration: none;">faced by many ethical issues</ins>. <ins style="font-weight: bold; text-decoration: none;">Eight in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites tentatively identified </ins>were <ins style="font-weight: bold; text-decoration: none;">mainly products of ester hydrolysis </ins>with <ins style="font-weight: bold; text-decoration: none;">or without additional dehydrogenation</ins>, <ins style="font-weight: bold; text-decoration: none;">N</ins>-<ins style="font-weight: bold; text-decoration: none;">dealkylation</ins>, <ins style="font-weight: bold; text-decoration: none;">monohydroxylation and oxidative defluorination with further oxidation to butanoic acid</ins>.&lt;br&gt; Fig. 1. &lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, 4F ADB liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL (0.37–4.1 ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL according to the reported cases) of SCRA and 1.5–2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 g</ins>/<ins style="font-weight: bold; text-decoration: none;">L of ethanol. The </ins>reported <ins style="font-weight: bold; text-decoration: none;">cases and reviews of </ins>the <ins style="font-weight: bold; text-decoration: none;">scientific literature suggest a possible synergistic effect between SCRAs </ins>and <ins style="font-weight: bold; text-decoration: none;">ethanol</ins>, <ins style="font-weight: bold; text-decoration: none;">because their combined use clearly increases their toxicity</ins>. <ins style="font-weight: bold; text-decoration: none;">The victim died due </ins>to <ins style="font-weight: bold; text-decoration: none;">severe necrotizing pancreatitis </ins>and <ins style="font-weight: bold; text-decoration: none;">acute kidney injury evolving into multi</ins>-<ins style="font-weight: bold; text-decoration: none;">organ failure 11 days after hospital admission . Studies have </ins>found <ins style="font-weight: bold; text-decoration: none;">no unequivocal synergistic effect between THC and ethanol </ins>at <ins style="font-weight: bold; text-decoration: none;">low or moderate ethanol doses [29</ins>, <ins style="font-weight: bold; text-decoration: none;">30]</ins>, <ins style="font-weight: bold; text-decoration: none;">but no data on high doses </ins>of <ins style="font-weight: bold; text-decoration: none;">ethanol are available. Given that THC and ethanol act on </ins>the <ins style="font-weight: bold; text-decoration: none;">same receptors, data on their simultaneous use may yield important insights in this regard</ins>.&lt;br&gt; Fungus C. elegans &lt;br&gt;Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225234&oldid=prev 2026-05-24T09:48:36Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:48, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">As previously mentioned</del>, <del style="font-weight: bold; text-decoration: none;">all </del>of the <del style="font-weight: bold; text-decoration: none;">compounds tested </del>in the present study <del style="font-weight: bold; text-decoration: none;">(</del>MDMB-PINACA, MDMB-<del style="font-weight: bold; text-decoration: none;">CHMICA</del>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA<del style="font-weight: bold; text-decoration: none;">) act as agonists at CB1 receptors (Banister et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have </del>no <del style="font-weight: bold; text-decoration: none;">known competing financial interests or personal relationships that could have appeared to influence </del>the <del style="font-weight: bold; text-decoration: none;">work reported in this paper. Second, we could not 5CL ADBA powder retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region </del>of <del style="font-weight: bold; text-decoration: none;">origin. Whether a recreational drug can be administered via vaping</del>, <del style="font-weight: bold; text-decoration: none;">depends on whether the </del>drug <del style="font-weight: bold; text-decoration: none;">becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There </del>is <del style="font-weight: bold; text-decoration: none;">difficulty in finding </del>the <del style="font-weight: bold; text-decoration: none;">right information about the NPS, defining their potency and confirmation </del>of <del style="font-weight: bold; text-decoration: none;">their existence in e-liquids or urine samples</del>.<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;</del>The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in a dose-dependent manner. A total of 5 mice in </del>the <del style="font-weight: bold; text-decoration: none;">JWH-081 </del>(5 <del style="font-weight: bold; text-decoration: none;">mg/kg, i</del>.<del style="font-weight: bold; text-decoration: none;">p</del>.<del style="font-weight: bold; text-decoration: none;">) treated group </del>and <del style="font-weight: bold; text-decoration: none;">6 mice </del>in <del style="font-weight: bold; text-decoration: none;">the 5CL ADBA powder JWH-210 </del>(<del style="font-weight: bold; text-decoration: none;">5 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">i</del>.<del style="font-weight: bold; text-decoration: none;">p</del>.) <del style="font-weight: bold; text-decoration: none;">treated group showed loss </del>of <del style="font-weight: bold; text-decoration: none;">traction, of which </del>4 <del style="font-weight: bold; text-decoration: none;">and 5 showed tremor, respectively</del>. <del style="font-weight: bold; text-decoration: none;">Memory retention </del>was <del style="font-weight: bold; text-decoration: none;">measured after the memory acquisition was tested </del>as <del style="font-weight: bold; text-decoration: none;">a probe trial.</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">About Powder JWH-2</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Legal status &lt;br&gt;JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent </del>and <del style="font-weight: bold; text-decoration: none;">dependable</del>, <del style="font-weight: bold; text-decoration: none;">and this product delivers on both fronts. Whether used in small</del>-<del style="font-weight: bold; text-decoration: none;">scale experiments or larger research projects, </del>the <del style="font-weight: bold; text-decoration: none;">compound maintains its integrity under recommended storage conditions</del>. <del style="font-weight: bold; text-decoration: none;">This ensures ease </del>of <del style="font-weight: bold; text-decoration: none;">handling and precise measurement during laboratory use</del>. <del style="font-weight: bold; text-decoration: none;">Each batch undergoes detailed verification to ensure purity</del>, <del style="font-weight: bold; text-decoration: none;">consistency</del>, <del style="font-weight: bold; text-decoration: none;">and accuracy, making it suitable for controlled experimental environments. This study was supported by </del>a <del style="font-weight: bold; text-decoration: none;">grant (13181MFDS654) </del>of the <del style="font-weight: bold; text-decoration: none;">National Institute </del>of <del style="font-weight: bold; text-decoration: none;">Food and Drug Safety Evaluation</del>, <del style="font-weight: bold; text-decoration: none;">Ministry </del>of <del style="font-weight: bold; text-decoration: none;">Food </del>and <del style="font-weight: bold; text-decoration: none;">Drug Safety</del>, <del style="font-weight: bold; text-decoration: none;">Republic </del>of <del style="font-weight: bold; text-decoration: none;">Kore</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;These synthetic cannabinoids act [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com/ 5CL ADBA powder] directly at cannabinoid CB1 and CB2 receptors as does Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol (Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC) found in marijuana, but have different chemical structures unrelated to Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC, different metabolism, and often greater toxicity </del>(<del style="font-weight: bold; text-decoration: none;">Fantegrossi et al., 2014</del>). <del style="font-weight: bold; text-decoration: none;">Discriminative stimulus effects </del>were <del style="font-weight: bold; text-decoration: none;">tested in rats trained to discriminate Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol (3 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">30-min pretreatment)</del>. <del style="font-weight: bold; text-decoration: none;">5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA </del>(<del style="font-weight: bold; text-decoration: none;">also known as 5F-ADB, 5F-ADB-PINACA</del>), <del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">CHIMICA</del>, <del style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">ADB-FUBINACA</del>, <del style="font-weight: bold; text-decoration: none;">and AMB-FUBINACA (also known as FUB-AMB</del>, <del style="font-weight: bold; text-decoration: none;">MMB-FUBINACA</del>) <del style="font-weight: bold; text-decoration: none;">were tested for in vivo cannabinoid-like effects to assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA </del>is <del style="font-weight: bold; text-decoration: none;">not detected by </del>commonly <del style="font-weight: bold; text-decoration: none;">available tests</del>. <del style="font-weight: bold; text-decoration: none;">He confirmed that he had </del>been <del style="font-weight: bold; text-decoration: none;">vaping </del>an <del style="font-weight: bold; text-decoration: none;">electronic cigarette </del>(<del style="font-weight: bold; text-decoration: none;">e-cigarette</del>) <del style="font-weight: bold; text-decoration: none;">earlier that day just before the onset of his symptoms</del>. <del style="font-weight: bold; text-decoration: none;">Metabolic acidosis </del>(<del style="font-weight: bold; text-decoration: none;">1/3</del>, <del style="font-weight: bold; text-decoration: none;">0</del>/<del style="font-weight: bold; text-decoration: none;">7</del>) and <del style="font-weight: bold; text-decoration: none;">respiratory acidosis </del>(<del style="font-weight: bold; text-decoration: none;">1</del>/<del style="font-weight: bold; text-decoration: none;">3, 0</del>/<del style="font-weight: bold; text-decoration: none;">7</del>)<del style="font-weight: bold; text-decoration: none;">, All 10 patients recovered with supportive care, including intubation and ventilation for one case</del>. In <del style="font-weight: bold; text-decoration: none;">3 cases ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA was the only substance detected, while </del>in seven <del style="font-weight: bold; text-decoration: none;">other substances of misuse were also </del>detected <del style="font-weight: bold; text-decoration: none;">including other SCRA</del>, <del style="font-weight: bold; text-decoration: none;">opioids</del>, <del style="font-weight: bold; text-decoration: none;">benzodiazepines cocaine and pregabali</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;In </del>the <del style="font-weight: bold; text-decoration: none;">present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, </del>and <del style="font-weight: bold; text-decoration: none;">water-maze test for learning</del>/<del style="font-weight: bold; text-decoration: none;">memory evaluation</del>. <del style="font-weight: bold; text-decoration: none;">Known for its stability and consistent composition, this compound </del>is <del style="font-weight: bold; text-decoration: none;">frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study</del>, <del style="font-weight: bold; text-decoration: none;">histopathological evaluation </del>was <del style="font-weight: bold; text-decoration: none;">performed </del>to <del style="font-weight: bold; text-decoration: none;">confirm the possibility of neurotoxicity of the tested substances by hematoxylin </del>and <del style="font-weight: bold; text-decoration: none;">eosin staining method from collected brain samples</del>. In the <del style="font-weight: bold; text-decoration: none;">present study</del>, <del style="font-weight: bold; text-decoration: none;">we evaluated </del>the <del style="font-weight: bold; text-decoration: none;">neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, </del>1<del style="font-weight: bold; text-decoration: none;">, 5 mg</del>/<del style="font-weight: bold; text-decoration: none;">kg)</del>. <del style="font-weight: bold; text-decoration: none;">Selecting powder JWH-210 demands careful evaluation </del>of <del style="font-weight: bold; text-decoration: none;">purity</del>, <del style="font-weight: bold; text-decoration: none;">legality</del>, <del style="font-weight: bold; text-decoration: none;">and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to 5CLADBA reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects</ins>, <ins style="font-weight: bold; text-decoration: none;">which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course </ins>of the <ins style="font-weight: bold; text-decoration: none;">psychoactive effects </ins>in <ins style="font-weight: bold; text-decoration: none;">human users. The purpose of </ins>the present study <ins style="font-weight: bold; text-decoration: none;">was to assess the abuse liability of 5F-</ins>MDMB-PINACA, MDMB-<ins style="font-weight: bold; text-decoration: none;">CHIMICA</ins>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. <ins style="font-weight: bold; text-decoration: none;">Since there is currently </ins>no <ins style="font-weight: bold; text-decoration: none;">robust measure of </ins>the <ins style="font-weight: bold; text-decoration: none;">reinforcing/rewarding effects </ins>of <ins style="font-weight: bold; text-decoration: none;">cannabinoids</ins>, drug <ins style="font-weight: bold; text-decoration: none;">discrimination </ins>is <ins style="font-weight: bold; text-decoration: none;">currently </ins>the <ins style="font-weight: bold; text-decoration: none;">best model for assessing abuse liability </ins>of <ins style="font-weight: bold; text-decoration: none;">cannabinoids</ins>. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">After </ins>the <ins style="font-weight: bold; text-decoration: none;">incubation, mixture was centrifuged </ins>(<ins style="font-weight: bold; text-decoration: none;">18,000 x g, 20 °C) for </ins>5 <ins style="font-weight: bold; text-decoration: none;">min and 0</ins>.<ins style="font-weight: bold; text-decoration: none;">5 μL of the supernatant was directly injected to the chromatographic system</ins>. <ins style="font-weight: bold; text-decoration: none;">In the next step, ammonium formate as salting agent was added to the mixture </ins>and <ins style="font-weight: bold; text-decoration: none;">incubated </ins>in <ins style="font-weight: bold; text-decoration: none;">a thermomixer </ins>(<ins style="font-weight: bold; text-decoration: none;">20 °C</ins>, <ins style="font-weight: bold; text-decoration: none;">1200 rpm) for 15 min</ins>. <ins style="font-weight: bold; text-decoration: none;">After vortex-mixing, the mixture was allowed to stand 5CLADBA at room temperature for 5 min</ins>. <ins style="font-weight: bold; text-decoration: none;">MS/MS experiments were performed in MRM (multiple reaction monitoring</ins>) <ins style="font-weight: bold; text-decoration: none;">mode with an isolation window </ins>of <ins style="font-weight: bold; text-decoration: none;">0.</ins>4 <ins style="font-weight: bold; text-decoration: none;">m/z</ins>. <ins style="font-weight: bold; text-decoration: none;">The MS measurement </ins>was <ins style="font-weight: bold; text-decoration: none;">performed in positive ion mode (except for some acidic compounds such </ins>as <ins style="font-weight: bold; text-decoration: none;">barbiturates</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert</ins>-<ins style="font-weight: bold; text-decoration: none;">leucine </ins>and <ins style="font-weight: bold; text-decoration: none;">indazole moieties remained unchanged</ins>, <ins style="font-weight: bold; text-decoration: none;">leading to the structure elucidation of a hydroxy-functional group at the 4</ins>-<ins style="font-weight: bold; text-decoration: none;">position of </ins>the <ins style="font-weight: bold; text-decoration: none;">butyl side chain by oxidative defluorination</ins>. <ins style="font-weight: bold; text-decoration: none;">The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence </ins>of <ins style="font-weight: bold; text-decoration: none;">dihydroxylated metabolites</ins>. <ins style="font-weight: bold; text-decoration: none;">The precursor ion</ins>, <ins style="font-weight: bold; text-decoration: none;">m/z 364 (B14</ins>, <ins style="font-weight: bold; text-decoration: none;">B5/B6) had </ins>a <ins style="font-weight: bold; text-decoration: none;">loss of 2 Da from m/z 366 indicated further dehydrogenation </ins>of the <ins style="font-weight: bold; text-decoration: none;">ester hydrolysis plus monohydroxylated metabolites. The presence </ins>of <ins style="font-weight: bold; text-decoration: none;">the product ion m/z 320</ins>, <ins style="font-weight: bold; text-decoration: none;">likely formed from a loss </ins>of <ins style="font-weight: bold; text-decoration: none;">carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) </ins>and <ins style="font-weight: bold; text-decoration: none;">indazole moiety in B13 (m/z 161). The precursor ion</ins>, <ins style="font-weight: bold; text-decoration: none;">m/z 350 showed a loss of 14 Da explaining the hydrolysis </ins>of <ins style="font-weight: bold; text-decoration: none;">methyl ester from 4F-MDMB-BINACA.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Fig. 2. </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA was hydrolysed via ester hydrolysis forming the 4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA ester hydrolysis metabolite </ins>(<ins style="font-weight: bold; text-decoration: none;">B22</ins>). <ins style="font-weight: bold; text-decoration: none;">Data obtained from the twenty urine samples </ins>were <ins style="font-weight: bold; text-decoration: none;">retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex</ins>-<ins style="font-weight: bold; text-decoration: none;">mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature</ins>, <ins style="font-weight: bold; text-decoration: none;">and 150 µL of purified water was added</ins>. <ins style="font-weight: bold; text-decoration: none;">High</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization </ins>(<ins style="font-weight: bold; text-decoration: none;">ESI</ins>) <ins style="font-weight: bold; text-decoration: none;">source operated in both positive and negative ion modes</ins>, <ins style="font-weight: bold; text-decoration: none;">to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC</ins>-<ins style="font-weight: bold; text-decoration: none;">C18 analytical column (2.7 μm</ins>, <ins style="font-weight: bold; text-decoration: none;">75 × 2.1 mm; Agilent Technologies</ins>, <ins style="font-weight: bold; text-decoration: none;">Santa Clara</ins>, <ins style="font-weight: bold; text-decoration: none;">CA</ins>, <ins style="font-weight: bold; text-decoration: none;">USA</ins>)<ins style="font-weight: bold; text-decoration: none;">.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Fig. 1. </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">This outcome was anticipated since CES-mediated hydrolysis </ins>is commonly <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb.com/ 5CLADBA] reported as the major metabolic pathway among the SCBs impacting the terminal ester group </ins>. <ins style="font-weight: bold; text-decoration: none;">Glucosides and sulfate metabolites have </ins>been <ins style="font-weight: bold; text-decoration: none;">reported with other SCBs where C. From these three samples, sample 2 contained only </ins>an <ins style="font-weight: bold; text-decoration: none;">ester hydrolysis metabolite </ins>(<ins style="font-weight: bold; text-decoration: none;">m/z 350</ins>). <ins style="font-weight: bold; text-decoration: none;">Both ester hydrolysis followed by oxidative defluorination to butanoic acid </ins>(<ins style="font-weight: bold; text-decoration: none;">B4</ins>, <ins style="font-weight: bold; text-decoration: none;">m</ins>/<ins style="font-weight: bold; text-decoration: none;">z 362</ins>) and <ins style="font-weight: bold; text-decoration: none;">monohydroxylation at tert-leucine moiety </ins>(<ins style="font-weight: bold; text-decoration: none;">B8, m</ins>/<ins style="font-weight: bold; text-decoration: none;">z 366) metabolites were found in 16</ins>/<ins style="font-weight: bold; text-decoration: none;">20 urine samples (Table 2</ins>). <ins style="font-weight: bold; text-decoration: none;">A </ins>In-<ins style="font-weight: bold; text-decoration: none;">vitro metabolites observed </ins>in <ins style="font-weight: bold; text-decoration: none;">common among respective </ins>seven <ins style="font-weight: bold; text-decoration: none;">most abundant metabolites in b C. The product ion </ins>detected <ins style="font-weight: bold; text-decoration: none;">at m/z 235</ins>, <ins style="font-weight: bold; text-decoration: none;">indicating loss of sulfate</ins>, <ins style="font-weight: bold; text-decoration: none;">confirmed the identity of the sulfation metabolite.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Fungus C. elegans </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Concentrations of 4F-MDMB-BINACA in </ins>the <ins style="font-weight: bold; text-decoration: none;">postmortem blood samples were 2.50 </ins>and <ins style="font-weight: bold; text-decoration: none;">2.34 ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL, which are in line with published data</ins>. <ins style="font-weight: bold; text-decoration: none;">Although the lethal dose of 4F-MDMB-BINACA </ins>is <ins style="font-weight: bold; text-decoration: none;">unknown</ins>, <ins style="font-weight: bold; text-decoration: none;">its concentration in postmortem blood samples </ins>was <ins style="font-weight: bold; text-decoration: none;">found </ins>to <ins style="font-weight: bold; text-decoration: none;">range between 0.10 </ins>and <ins style="font-weight: bold; text-decoration: none;">2.90 ng/mL </ins>. In <ins style="font-weight: bold; text-decoration: none;">SCRA-related cases in which </ins>the <ins style="font-weight: bold; text-decoration: none;">deceased suffered from heart disease</ins>, the <ins style="font-weight: bold; text-decoration: none;">SCRA concentration in the postmortem blood was less than </ins>1 <ins style="font-weight: bold; text-decoration: none;">ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL </ins>. <ins style="font-weight: bold; text-decoration: none;">Concentrations </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRAs in postmortem cases cover a wide range ; however</ins>, <ins style="font-weight: bold; text-decoration: none;">some reports of survival have also been published—even at relatively high blood SCRA concentrations [19</ins>, <ins style="font-weight: bold; text-decoration: none;">20</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225164&oldid=prev 2026-05-24T09:41:19Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:41, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Our findings revealed that both victims consumed large amounts of alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L</del>, <del style="font-weight: bold; text-decoration: none;">respectively). Forensic autopsy </del>of <del style="font-weight: bold; text-decoration: none;">both victims was performed four days after </del>the <del style="font-weight: bold; text-decoration: none;">time of death following </del>the <del style="font-weight: bold; text-decoration: none;">Recommendation No.R </del>(<del style="font-weight: bold; text-decoration: none;">99)3 of the Council of Europe on medico</del>-<del style="font-weight: bold; text-decoration: none;">legal autopsies. Elegans demonstrated the ability to form all of the in</del>-<del style="font-weight: bold; text-decoration: none;">vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites</del>, <del style="font-weight: bold; text-decoration: none;">as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence of the in</del>-<del style="font-weight: bold; text-decoration: none;">vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover</del>, <del style="font-weight: bold; text-decoration: none;">genetic makeup, physiological conditions (age, gender [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com/ JWH-210 powder] and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes</del>, and <del style="font-weight: bold; text-decoration: none;">obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity and matrix effects bias for each metabolite.&lt;br&gt;Victim B also brought "something resembling a drug" (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half</del>-<del style="font-weight: bold; text-decoration: none;">maximal effective concentration (EC50</del>) <del style="font-weight: bold; text-decoration: none;">of 4F-MDMB-BINACA is 5.69 nM </del>(<del style="font-weight: bold; text-decoration: none;">2</del>.<del style="font-weight: bold; text-decoration: none;">76–11</del>.<del style="font-weight: bold; text-decoration: none;">0 nM) on CB1</del>, <del style="font-weight: bold; text-decoration: none;">and 0.69 nM (0.30–1.56 nM</del>) <del style="font-weight: bold; text-decoration: none;">on CB2</del>, <del style="font-weight: bold; text-decoration: none;">in vitro half</del>-<del style="font-weight: bold; text-decoration: none;">life (t1/2) is 10.27 min . It is usually available as a powder</del>, <del style="font-weight: bold; text-decoration: none;">liquid (vapor fluid), or herbal plant mixtur</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Although there were reports on the metabolism of 4F-MDMB-BINACA </del>using <del style="font-weight: bold; text-decoration: none;">in</del>-<del style="font-weight: bold; text-decoration: none;">vivo and various in</del>-<del style="font-weight: bold; text-decoration: none;">vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons </del>. The <del style="font-weight: bold; text-decoration: none;">hepatic cell line HepG2 is often used as an initial screen as it is </del>known to <del style="font-weight: bold; text-decoration: none;">produce high reproducibility results with relatively stable enzyme concentration</del>, <del style="font-weight: bold; text-decoration: none;">although they are limited </del>by the <del style="font-weight: bold; text-decoration: none;">low-level expression </del>of <del style="font-weight: bold; text-decoration: none;">several metabolizing enzymes</del>, <del style="font-weight: bold; text-decoration: none;">including </del>the <del style="font-weight: bold; text-decoration: none;">cytochrome P450 (CYP) class </del>of <del style="font-weight: bold; text-decoration: none;">proteins [17, 18]</del>. <del style="font-weight: bold; text-decoration: none;">In-vitro metabolism studies are generally used to complement </del>these <del style="font-weight: bold; text-decoration: none;">data using perfused organs</del>, <del style="font-weight: bold; text-decoration: none;">tissue </del>or <del style="font-weight: bold; text-decoration: none;">cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12</del>,<del style="font-weight: bold; text-decoration: none;">13,14,15,16]. Since most SCBs are found extensively </del>in <del style="font-weight: bold; text-decoration: none;">metabolized forms in urine</del>, <del style="font-weight: bold; text-decoration: none;">the identification of metabolites is </del>of <del style="font-weight: bold; text-decoration: none;">vital importance for forensic </del>and <del style="font-weight: bold; text-decoration: none;">clinical toxicologists</del>. <del style="font-weight: bold; text-decoration: none;">Identifying SCB intake </del>and <del style="font-weight: bold; text-decoration: none;">its correlating specific adverse effects require rapid elucidation </del>of <del style="font-weight: bold; text-decoration: none;">these SCBs</del>. The <del style="font-weight: bold; text-decoration: none;">proliferation of SCBs has become </del>a <del style="font-weight: bold; text-decoration: none;">global challenge as new compounds </del>are <del style="font-weight: bold; text-decoration: none;">rapidly introduced into the illegal drug market </del>to <del style="font-weight: bold; text-decoration: none;">evade existing </del>drug <del style="font-weight: bold; text-decoration: none;">law</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Moreover, </del>a <del style="font-weight: bold; text-decoration: none;">study conducted </del>in the <del style="font-weight: bold; text-decoration: none;">United Kingdom investigated components of e</del>-<del style="font-weight: bold; text-decoration: none;">liquids in 112 samples originating from prisoners</del>, <del style="font-weight: bold; text-decoration: none;">teenagers </del>and <del style="font-weight: bold; text-decoration: none;">test purchases of commercially available e</del>-<del style="font-weight: bold; text-decoration: none;">cigarettes taken between 2014 and 2021 </del>. <del style="font-weight: bold; text-decoration: none;">This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA</del>. <del style="font-weight: bold; text-decoration: none;">Results </del>of <del style="font-weight: bold; text-decoration: none;">the DOA test (including testing for amphetamines</del>, <del style="font-weight: bold; text-decoration: none;">methamphetamines</del>, <del style="font-weight: bold; text-decoration: none;">barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative</del>. <del style="font-weight: bold; text-decoration: none;">We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA </del>after <del style="font-weight: bold; text-decoration: none;">vaping. There are several pitfalls in </del>the <del style="font-weight: bold; text-decoration: none;">detection of SCRA in samples taken from the patient</del>.&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Data availabili</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Effects of individual doses were compared to the vehicle control value using </del>a <del style="font-weight: bold; text-decoration: none;">priori contrasts</del>. <del style="font-weight: bold; text-decoration: none;">Response</del>-<del style="font-weight: bold; text-decoration: none;">rate data were analyzed by one-way repeated-measure analysis </del>of <del style="font-weight: bold; text-decoration: none;">variance</del>. <del style="font-weight: bold; text-decoration: none;">Percent drug-appropriate responding </del>was <del style="font-weight: bold; text-decoration: none;">shown only if at JWH-210 powder least three rats completed </del>the <del style="font-weight: bold; text-decoration: none;">first fixed ratio</del>, <del style="font-weight: bold; text-decoration: none;">whereas all rats are shown for the response rate dat</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS represents a significant advancement </del>in <del style="font-weight: bold; text-decoration: none;">the field of drug detection</del>, <del style="font-weight: bold; text-decoration: none;">offering higher sensitivity</del>, <del style="font-weight: bold; text-decoration: none;">specificity</del>, and <del style="font-weight: bold; text-decoration: none;">a broader spectrum of detectable substances</del>. <del style="font-weight: bold; text-decoration: none;">Despite all negative results </del>in <del style="font-weight: bold; text-decoration: none;">the point</del>-<del style="font-weight: bold; text-decoration: none;">of-care test for recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">the liquid chromatography</del>-<del style="font-weight: bold; text-decoration: none;">quadrupole time</del>-<del style="font-weight: bold; text-decoration: none;">of</del>-<del style="font-weight: bold; text-decoration: none;">flight mass spectrometry </del>(<del style="font-weight: bold; text-decoration: none;">LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS</del>) <del style="font-weight: bold; text-decoration: none;">analysis showed that the liquid of the e</del>-<del style="font-weight: bold; text-decoration: none;">cigarette contained </del>ADB-<del style="font-weight: bold; text-decoration: none;">BUTINACA</del>, <del style="font-weight: bold; text-decoration: none;">a </del>synthetic cannabinoid. <del style="font-weight: bold; text-decoration: none;">We report a 27</del>-<del style="font-weight: bold; text-decoration: none;">year-old man who was admitted to </del>the <del style="font-weight: bold; text-decoration: none;">emergency room because </del>of <del style="font-weight: bold; text-decoration: none;">sudden JWH-210 powder headache</del>, <del style="font-weight: bold; text-decoration: none;">nausea</del>, <del style="font-weight: bold; text-decoration: none;">vertigo</del>, <del style="font-weight: bold; text-decoration: none;">red eyes </del>and <del style="font-weight: bold; text-decoration: none;">palpitations</del>. <del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids are gaining popularity globally </del>and <del style="font-weight: bold; text-decoration: none;">detection is not commonly available.</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Data availability </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">When clinical presentation and/or initial DOA </del>testing <del style="font-weight: bold; text-decoration: none;">results are inconclusive</del>, <del style="font-weight: bold; text-decoration: none;">additional testing with LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF-MS can be valuable </del>and is <del style="font-weight: bold; text-decoration: none;">recommended. SCRAs and other NPS may not be detected </del>by <del style="font-weight: bold; text-decoration: none;">point</del>-of<del style="font-weight: bold; text-decoration: none;">-care DOA tests</del>. In <del style="font-weight: bold; text-decoration: none;">this case</del>, the <del style="font-weight: bold; text-decoration: none;">point</del>-of-<del style="font-weight: bold; text-decoration: none;">care DOA urine screening was not able to detect the synthetic cannabinoid ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINAC</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">As previously mentioned</ins>, <ins style="font-weight: bold; text-decoration: none;">all </ins>of the <ins style="font-weight: bold; text-decoration: none;">compounds tested in </ins>the <ins style="font-weight: bold; text-decoration: none;">present study </ins>(<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">PINACA, MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">CHMICA</ins>, <ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">ADB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA</ins>, and <ins style="font-weight: bold; text-decoration: none;">AMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA</ins>) <ins style="font-weight: bold; text-decoration: none;">act as agonists at CB1 receptors </ins>(<ins style="font-weight: bold; text-decoration: none;">Banister et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2015, 2016; Gamage et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2018</ins>), <ins style="font-weight: bold; text-decoration: none;">which suggests these compounds will produce Δ9-THC</ins>-<ins style="font-weight: bold; text-decoration: none;">like effects</ins>, <ins style="font-weight: bold; text-decoration: none;">including abuse liabilit</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Demographic and clinical features are recorded and blood and/or urine samples analysed </ins>using <ins style="font-weight: bold; text-decoration: none;">high</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution accurate mass liquid chromatography</ins>-<ins style="font-weight: bold; text-decoration: none;">mass spectrometry</ins>. The <ins style="font-weight: bold; text-decoration: none;">authors declare that they have no </ins>known <ins style="font-weight: bold; text-decoration: none;">competing financial interests or personal relationships that could have appeared </ins>to <ins style="font-weight: bold; text-decoration: none;">influence the work reported in this paper. Second</ins>, <ins style="font-weight: bold; text-decoration: none;">we could not 5CL ADBA powder retrieve further detailed information about the e-cigarette that was used </ins>by the <ins style="font-weight: bold; text-decoration: none;">patient such as the label or the region </ins>of <ins style="font-weight: bold; text-decoration: none;">origin. Whether a recreational drug can be administered via vaping</ins>, <ins style="font-weight: bold; text-decoration: none;">depends on whether the drug becomes volatile under </ins>the <ins style="font-weight: bold; text-decoration: none;">evaporation temperature </ins>of <ins style="font-weight: bold; text-decoration: none;">the e-cigarette</ins>. <ins style="font-weight: bold; text-decoration: none;">Of </ins>these <ins style="font-weight: bold; text-decoration: none;">samples</ins>, <ins style="font-weight: bold; text-decoration: none;">22 contained one </ins>or <ins style="font-weight: bold; text-decoration: none;">more SCRAs</ins>, <ins style="font-weight: bold; text-decoration: none;">THC was only detected </ins>in <ins style="font-weight: bold; text-decoration: none;">11 samples</ins>, <ins style="font-weight: bold; text-decoration: none;">only one contained cannabidiol and 6 contained a mixture </ins>of <ins style="font-weight: bold; text-decoration: none;">THC </ins>and <ins style="font-weight: bold; text-decoration: none;">cannabidiol</ins>. <ins style="font-weight: bold; text-decoration: none;">There is difficulty in finding the right information about the NPS, defining their potency </ins>and <ins style="font-weight: bold; text-decoration: none;">confirmation </ins>of <ins style="font-weight: bold; text-decoration: none;">their existence in e-liquids or urine samples</ins>.<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;</ins>The <ins style="font-weight: bold; text-decoration: none;">findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that </ins>a <ins style="font-weight: bold; text-decoration: none;">compound will be abused by humans, and cannabinoids </ins>are <ins style="font-weight: bold; text-decoration: none;">well-known </ins>to <ins style="font-weight: bold; text-decoration: none;">produce active </ins>drug<ins style="font-weight: bold; text-decoration: none;">-seeking in human</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in </ins>a <ins style="font-weight: bold; text-decoration: none;">dose-dependent manner. A total of 5 mice </ins>in the <ins style="font-weight: bold; text-decoration: none;">JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">081 (5 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">i.p.) treated group </ins>and <ins style="font-weight: bold; text-decoration: none;">6 mice in the 5CL ADBA powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 (5 mg/kg, i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.<ins style="font-weight: bold; text-decoration: none;">) treated group showed loss </ins>of <ins style="font-weight: bold; text-decoration: none;">traction</ins>, <ins style="font-weight: bold; text-decoration: none;">of which 4 and 5 showed tremor</ins>, <ins style="font-weight: bold; text-decoration: none;">respectively</ins>. <ins style="font-weight: bold; text-decoration: none;">Memory retention was measured </ins>after the <ins style="font-weight: bold; text-decoration: none;">memory acquisition was tested as a probe trial</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">About Powder JWH-2</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Legal status </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder offers a reliable solution for laboratories seeking </ins>a <ins style="font-weight: bold; text-decoration: none;">compound that meets stringent requirements</ins>. <ins style="font-weight: bold; text-decoration: none;">Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small</ins>-<ins style="font-weight: bold; text-decoration: none;">scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease </ins>of <ins style="font-weight: bold; text-decoration: none;">handling and precise measurement during laboratory use</ins>. <ins style="font-weight: bold; text-decoration: none;">Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study </ins>was <ins style="font-weight: bold; text-decoration: none;">supported by a grant (13181MFDS654) of </ins>the <ins style="font-weight: bold; text-decoration: none;">National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety</ins>, <ins style="font-weight: bold; text-decoration: none;">Republic of Kore</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">These synthetic cannabinoids act [https://cannabinoidsrc4f</ins>-<ins style="font-weight: bold; text-decoration: none;">adb.com/ 5CL ADBA powder] directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC) found </ins>in <ins style="font-weight: bold; text-decoration: none;">marijuana</ins>, <ins style="font-weight: bold; text-decoration: none;">but have different chemical structures unrelated to Δ9-THC</ins>, <ins style="font-weight: bold; text-decoration: none;">different metabolism</ins>, and <ins style="font-weight: bold; text-decoration: none;">often greater toxicity (Fantegrossi et al., 2014)</ins>. <ins style="font-weight: bold; text-decoration: none;">Discriminative stimulus effects were tested </ins>in <ins style="font-weight: bold; text-decoration: none;">rats trained to discriminate Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol (3 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">30</ins>-<ins style="font-weight: bold; text-decoration: none;">min pretreatment). 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">PINACA </ins>(<ins style="font-weight: bold; text-decoration: none;">also known as 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">ADB, 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">ADB-PINACA</ins>)<ins style="font-weight: bold; text-decoration: none;">, MDMB-CHIMICA, MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, </ins>ADB-<ins style="font-weight: bold; text-decoration: none;">FUBINACA, and AMB-FUBINACA (also known as FUB-AMB</ins>, <ins style="font-weight: bold; text-decoration: none;">MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;As </ins>synthetic cannabinoid <ins style="font-weight: bold; text-decoration: none;">receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests</ins>. <ins style="font-weight: bold; text-decoration: none;">He confirmed that he had been vaping an electronic cigarette (e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette) earlier that day just before </ins>the <ins style="font-weight: bold; text-decoration: none;">onset </ins>of <ins style="font-weight: bold; text-decoration: none;">his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3</ins>, <ins style="font-weight: bold; text-decoration: none;">0/7)</ins>, <ins style="font-weight: bold; text-decoration: none;">All 10 patients recovered with supportive care</ins>, <ins style="font-weight: bold; text-decoration: none;">including intubation </ins>and <ins style="font-weight: bold; text-decoration: none;">ventilation for one case</ins>. <ins style="font-weight: bold; text-decoration: none;">In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine </ins>and <ins style="font-weight: bold; text-decoration: none;">pregabali&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">In the present study, we performed various methods based on animal behavioral </ins>testing <ins style="font-weight: bold; text-decoration: none;">including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation</ins>, <ins style="font-weight: bold; text-decoration: none;">and water</ins>-<ins style="font-weight: bold; text-decoration: none;">maze test for learning/memory evaluation. Known for its stability </ins>and <ins style="font-weight: bold; text-decoration: none;">consistent composition, this compound </ins>is <ins style="font-weight: bold; text-decoration: none;">frequently utilized </ins>by <ins style="font-weight: bold; text-decoration: none;">professionals seeking reliable materials for laboratory</ins>-<ins style="font-weight: bold; text-decoration: none;">based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity </ins>of <ins style="font-weight: bold; text-decoration: none;">the tested substances by hematoxylin and eosin staining method from collected brain samples</ins>. In <ins style="font-weight: bold; text-decoration: none;">the present study</ins>, <ins style="font-weight: bold; text-decoration: none;">we evaluated </ins>the <ins style="font-weight: bold; text-decoration: none;">neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 demands careful evaluation </ins>of <ins style="font-weight: bold; text-decoration: none;">purity, legality, and supplier credibility. Prices for research</ins>-<ins style="font-weight: bold; text-decoration: none;">grade JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 vary significantly based on quantity, purity, and vendor complianc</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225141&oldid=prev 2026-05-24T09:39:15Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:39, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those adb butinaca </del>of <del style="font-weight: bold; text-decoration: none;">Δ9-THC </del>(<del style="font-weight: bold; text-decoration: none;">Bannister and Connor, 2018</del>)<del style="font-weight: bold; text-decoration: none;">, </del>and <del style="font-weight: bold; text-decoration: none;">MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al</del>., <del style="font-weight: bold; text-decoration: none;">2018</del>). <del style="font-weight: bold; text-decoration: none;">The chemical structures </del>of the <del style="font-weight: bold; text-decoration: none;">recent synthetic cannabinoids are unlike that </del>of <del style="font-weight: bold; text-decoration: none;">Δ9-THC, but are largely based on </del>the <del style="font-weight: bold; text-decoration: none;">structure of older synthetic cannabinoids that are known to have substantial abuse liability </del>(<del style="font-weight: bold; text-decoration: none;">Fig. 1</del>). <del style="font-weight: bold; text-decoration: none;">All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar </del>to <del style="font-weight: bold; text-decoration: none;">those </del>of <del style="font-weight: bold; text-decoration: none;">Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC</del>, <del style="font-weight: bold; text-decoration: none;">which suggests they may have abuse liability similar to that </del>of <del style="font-weight: bold; text-decoration: none;">Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC</del>. <del style="font-weight: bold; text-decoration: none;">Subsequent testing identified 5F</del>-<del style="font-weight: bold; text-decoration: none;">ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014</del>. <del style="font-weight: bold; text-decoration: none;">AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA produced tremors </del>and <del style="font-weight: bold; text-decoration: none;">may </del>be <del style="font-weight: bold; text-decoration: none;">of increased risk </del>in <del style="font-weight: bold; text-decoration: none;">human recreational users</del>.&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Michael </del>B <del style="font-weight: bold; text-decoration: none;">Gatch &lt;br&gt;These findings are </del>in <del style="font-weight: bold; text-decoration: none;">agreement </del>with <del style="font-weight: bold; text-decoration: none;">earlier studies showing the synthetic cannabinoids substitute for the discriminative stimulus effects </del>of <del style="font-weight: bold; text-decoration: none;">Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC </del>(<del style="font-weight: bold; text-decoration: none;">see review by Wiley et al</del>., <del style="font-weight: bold; text-decoration: none;">2017</del>). <del style="font-weight: bold; text-decoration: none;">Pretreatment times and dose ranges for the drug discrimination assay </del>were <del style="font-weight: bold; text-decoration: none;">selected based </del>on the <del style="font-weight: bold; text-decoration: none;">time </del>of <del style="font-weight: bold; text-decoration: none;">peak depression </del>in <del style="font-weight: bold; text-decoration: none;">the locomotor activity assay </del>in <del style="font-weight: bold; text-decoration: none;">mice. As mentioned previously</del>, <del style="font-weight: bold; text-decoration: none;">short</del>-<del style="font-weight: bold; text-decoration: none;">onset compounds have a greater abuse liability; further</del>, <del style="font-weight: bold; text-decoration: none;">compounds that have fewer adverse effects while </del>they are <del style="font-weight: bold; text-decoration: none;">active are likely to be preferred. All five </del>of the <del style="font-weight: bold; text-decoration: none;">compounds in the present study fully substituted with a pretreatment time </del>of <del style="font-weight: bold; text-decoration: none;">15 min</del>, <del style="font-weight: bold; text-decoration: none;">suggesting a rapid onset of the discriminative stimulus effects</del>. <del style="font-weight: bold; text-decoration: none;">All of the cathinones fully substituted for the discriminative stimulus effects of Δ9</del>-<del style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol </del>(<del style="font-weight: bold; text-decoration: none;">≥80% drug-appropriate responding</del>). <del style="font-weight: bold; text-decoration: none;">Because response suppression may compromise stimulus control</del>, <del style="font-weight: bold; text-decoration: none;">rats failing to complete at least ten responses during </del>the <del style="font-weight: bold; text-decoration: none;">test session were excluded from the analysis </del>of <del style="font-weight: bold; text-decoration: none;">the discriminative stimulus </del>effects of <del style="font-weight: bold; text-decoration: none;">that dose </del>of <del style="font-weight: bold; text-decoration: none;">test compoun</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">4. Drugs </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Short-onset</del>, <del style="font-weight: bold; text-decoration: none;">short</del>-<del style="font-weight: bold; text-decoration: none;">acting compounds have a greater abuse liability</del>, and <del style="font-weight: bold; text-decoration: none;">long-acting compounds pose problems </del>of <del style="font-weight: bold; text-decoration: none;">long</del>-<del style="font-weight: bold; text-decoration: none;">acting adverse effects </del>and <del style="font-weight: bold; text-decoration: none;">interactions with other drugs</del>. <del style="font-weight: bold; text-decoration: none;">The duration </del>of <del style="font-weight: bold; text-decoration: none;">action </del>of the <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoids tested using the 8-h protocol have varied widely</del>, <del style="font-weight: bold; text-decoration: none;">with some producing a duration of action no longer than 1 h</del>, <del style="font-weight: bold; text-decoration: none;">others producing a duration of action between 1–2 h</del>, and <del style="font-weight: bold; text-decoration: none;">others lasting more than 2 h</del>. <del style="font-weight: bold; text-decoration: none;">There seems to be </del>a <del style="font-weight: bold; text-decoration: none;">trend </del>of <del style="font-weight: bold; text-decoration: none;">newer synthetic cannabinoids being more potent than earlier compounds. All </del>of the <del style="font-weight: bold; text-decoration: none;">compounds tested </del>in the <del style="font-weight: bold; text-decoration: none;">present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function </del>of <del style="font-weight: bold; text-decoration: none;">time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min</del>.&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Michael B Gat</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at <del style="font-weight: bold; text-decoration: none;">adb butinaca </del>least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate </del>in a <del style="font-weight: bold; text-decoration: none;">dose-dependent manner</del>. <del style="font-weight: bold; text-decoration: none;">A total of 5 mice </del>in the <del style="font-weight: bold; text-decoration: none;">JWH</del>-<del style="font-weight: bold; text-decoration: none;">081 (5 mg/kg</del>, <del style="font-weight: bold; text-decoration: none;">i.p.) treated group and 6 mice in </del>the <del style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb.com/ adb butinaca] JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 </del>(<del style="font-weight: bold; text-decoration: none;">5 mg/kg, i.p.</del>) <del style="font-weight: bold; text-decoration: none;">treated group </del>showed <del style="font-weight: bold; text-decoration: none;">loss </del>of <del style="font-weight: bold; text-decoration: none;">traction</del>, <del style="font-weight: bold; text-decoration: none;">of which 4 and 5 showed tremor, respectively</del>. <del style="font-weight: bold; text-decoration: none;">Memory retention was measured after the memory acquisition was tested as </del>a <del style="font-weight: bold; text-decoration: none;">probe trial.&lt;br&gt;About Powder JWH</del>-<del style="font-weight: bold; text-decoration: none;">2&lt;br&gt;&lt;br&gt;The findings produce an apparent paradox, since CPP and self</del>-<del style="font-weight: bold; text-decoration: none;">administration predict with high reliability </del>the <del style="font-weight: bold; text-decoration: none;">likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;&lt;br&gt;Buy Jwh</del>-210 <del style="font-weight: bold; text-decoration: none;">at USA K2 INCENSE STORE and enjoy premium quality</del>, <del style="font-weight: bold; text-decoration: none;">flexible quantities</del>, <del style="font-weight: bold; text-decoration: none;">and fast</del>, <del style="font-weight: bold; text-decoration: none;">secure shipping. Fast shipping </del>and <del style="font-weight: bold; text-decoration: none;">pure product-highly recommended for anyone needing quality incense ingredients</del>.<del style="font-weight: bold; text-decoration: none;">" 🌟🌟🌟🌟🌟 You can buy jwh-210 online in quantities of adb butinaca 10g, 30g, 50g, 100g, 150g, </del>and <del style="font-weight: bold; text-decoration: none;">200g at USA K2 INCENSE STORE for premium quality and discreet shipping. In some areas, it </del>is <del style="font-weight: bold; text-decoration: none;">classified as a controlled substance, while in others, it may be legal for research or incense use. The legal status of jwh-210 varies by country and region</del>.&lt;br&gt; <del style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">In case of cannabis </del>or <del style="font-weight: bold; text-decoration: none;">Δ9-tetrahydrocannabinol</del>, <del style="font-weight: bold; text-decoration: none;">there are many adb butinaca previous studies regarding </del>with <del style="font-weight: bold; text-decoration: none;">their dependence potential </del>and <del style="font-weight: bold; text-decoration: none;">neurotoxicity (Cororan, et al</del>.<del style="font-weight: bold; text-decoration: none;">, 1974; Harris, et al., 1974; Leite </del>and <del style="font-weight: bold; text-decoration: none;">Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every </del>other <del style="font-weight: bold; text-decoration: none;">day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and the first trial was performed 2 h after the last administration.&lt;br&gt; How to Choose Powder JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 &lt;br&gt;This dual-use nature underscores the importance </del>of <del style="font-weight: bold; text-decoration: none;">responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 to distinguish between legal and illegal compounds in seized materials</del>. <del style="font-weight: bold; text-decoration: none;">For those seeking a dependable compound for analytical purposes</del>, <del style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory</del>-<del style="font-weight: bold; text-decoration: none;">based research.&lt;br&gt; Is JWH-210 Legal? &lt;br&gt;To evaluate whether the changes </del>of <del style="font-weight: bold; text-decoration: none;">coordinative functions by CNS damages were due to test substances, rota</del>-<del style="font-weight: bold; text-decoration: none;">rod test </del>was <del style="font-weight: bold; text-decoration: none;">performed using Rota-rod apparatus (Daejong, Seoul, Korea). The test apparatus for the locomotor activity test was designed </del>to <del style="font-weight: bold; text-decoration: none;">measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in </del>the <del style="font-weight: bold; text-decoration: none;">chamber. In both tests, a group of mice were treated with negative control (vehicle, 1 mg/kg, i.p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of the three doses of test substances (0.1, 1, 5 mg/kg, i.p.) once every other day for 10 day</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Our findings revealed that both victims consumed large amounts </ins>of <ins style="font-weight: bold; text-decoration: none;">alcohol preceding their deaths (blood alcohol concentrations </ins>(<ins style="font-weight: bold; text-decoration: none;">BAC</ins>) <ins style="font-weight: bold; text-decoration: none;">were 2.11 </ins>and <ins style="font-weight: bold; text-decoration: none;">2</ins>.<ins style="font-weight: bold; text-decoration: none;">49 g/L</ins>, <ins style="font-weight: bold; text-decoration: none;">respectively</ins>). <ins style="font-weight: bold; text-decoration: none;">Forensic autopsy </ins>of <ins style="font-weight: bold; text-decoration: none;">both victims was performed four days after </ins>the <ins style="font-weight: bold; text-decoration: none;">time </ins>of <ins style="font-weight: bold; text-decoration: none;">death following </ins>the <ins style="font-weight: bold; text-decoration: none;">Recommendation No.R </ins>(<ins style="font-weight: bold; text-decoration: none;">99</ins>)<ins style="font-weight: bold; text-decoration: none;">3 of the Council of Europe on medico-legal autopsies</ins>. <ins style="font-weight: bold; text-decoration: none;">Elegans demonstrated the ability </ins>to <ins style="font-weight: bold; text-decoration: none;">form all </ins>of <ins style="font-weight: bold; text-decoration: none;">the in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites</ins>, <ins style="font-weight: bold; text-decoration: none;">as well as identifying possible drug toxicities for emerging SCBs. Thus, identification of the relevant urinary markers was based primarily upon the prevalence </ins>of <ins style="font-weight: bold; text-decoration: none;">the in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio</ins>. <ins style="font-weight: bold; text-decoration: none;">Moreover, genetic makeup, physiological conditions (age, gender [https://cannabinoidsrc4f</ins>-<ins style="font-weight: bold; text-decoration: none;">adb</ins>.<ins style="font-weight: bold; text-decoration: none;">com/ JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 powder] </ins>and <ins style="font-weight: bold; text-decoration: none;">ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should </ins>be <ins style="font-weight: bold; text-decoration: none;">noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences </ins>in <ins style="font-weight: bold; text-decoration: none;">ionization capacity and matrix effects bias for each metabolite</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Victim B also brought "something resembling a drug" (unrecognizable by Witness A) from his cousin (Witness </ins>B<ins style="font-weight: bold; text-decoration: none;">) </ins>in <ins style="font-weight: bold; text-decoration: none;">a cigarette box and mixed this substance </ins>with <ins style="font-weight: bold; text-decoration: none;">their tobacco. The half-maximal effective concentration (EC50) </ins>of <ins style="font-weight: bold; text-decoration: none;">4F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB-BINACA is 5.69 nM </ins>(<ins style="font-weight: bold; text-decoration: none;">2.76–11.0 nM) on CB1, and 0.69 nM (0.30–1</ins>.<ins style="font-weight: bold; text-decoration: none;">56 nM) on CB2</ins>, <ins style="font-weight: bold; text-decoration: none;">in vitro half-life (t1/2</ins>) <ins style="font-weight: bold; text-decoration: none;">is 10</ins>.<ins style="font-weight: bold; text-decoration: none;">27 min . It is usually available as a powder, liquid (vapor fluid), or herbal plant mixtur&lt;br&gt;&lt;br&gt;&lt;br&gt;Although there </ins>were <ins style="font-weight: bold; text-decoration: none;">reports </ins>on the <ins style="font-weight: bold; text-decoration: none;">metabolism </ins>of <ins style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA using </ins>in<ins style="font-weight: bold; text-decoration: none;">-vivo and various </ins>in<ins style="font-weight: bold; text-decoration: none;">-vitro models</ins>, <ins style="font-weight: bold; text-decoration: none;">studies were either conducted using small in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration</ins>, <ins style="font-weight: bold; text-decoration: none;">although </ins>they are <ins style="font-weight: bold; text-decoration: none;">limited by the low-level expression </ins>of <ins style="font-weight: bold; text-decoration: none;">several metabolizing enzymes, including </ins>the <ins style="font-weight: bold; text-decoration: none;">cytochrome P450 (CYP) class </ins>of <ins style="font-weight: bold; text-decoration: none;">proteins [17</ins>, <ins style="font-weight: bold; text-decoration: none;">18]</ins>. <ins style="font-weight: bold; text-decoration: none;">In</ins>-<ins style="font-weight: bold; text-decoration: none;">vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes </ins>(<ins style="font-weight: bold; text-decoration: none;">HLM</ins>) <ins style="font-weight: bold; text-decoration: none;">have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]</ins>. <ins style="font-weight: bold; text-decoration: none;">Since most SCBs are found extensively in metabolized forms in urine</ins>, the <ins style="font-weight: bold; text-decoration: none;">identification of metabolites is </ins>of <ins style="font-weight: bold; text-decoration: none;">vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse </ins>effects <ins style="font-weight: bold; text-decoration: none;">require rapid elucidation </ins>of <ins style="font-weight: bold; text-decoration: none;">these SCBs. The proliferation </ins>of <ins style="font-weight: bold; text-decoration: none;">SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Moreover</ins>, <ins style="font-weight: bold; text-decoration: none;">a study conducted in the United Kingdom investigated components of e</ins>-<ins style="font-weight: bold; text-decoration: none;">liquids in 112 samples originating from prisoners</ins>, <ins style="font-weight: bold; text-decoration: none;">teenagers </ins>and <ins style="font-weight: bold; text-decoration: none;">test purchases </ins>of <ins style="font-weight: bold; text-decoration: none;">commercially available e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarettes taken between 2014 </ins>and <ins style="font-weight: bold; text-decoration: none;">2021 </ins>. <ins style="font-weight: bold; text-decoration: none;">This is the first case report that describes the toxicological symptoms </ins>of <ins style="font-weight: bold; text-decoration: none;">vaping ADB-BUTINACA. Results </ins>of the <ins style="font-weight: bold; text-decoration: none;">DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone</ins>, <ins style="font-weight: bold; text-decoration: none;">opioids</ins>, <ins style="font-weight: bold; text-decoration: none;">cannabis</ins>, <ins style="font-weight: bold; text-decoration: none;">tricyclic antidepressants) were available within 30 minutes </ins>and <ins style="font-weight: bold; text-decoration: none;">were all negative</ins>. <ins style="font-weight: bold; text-decoration: none;">We report </ins>a <ins style="font-weight: bold; text-decoration: none;">case </ins>of <ins style="font-weight: bold; text-decoration: none;">an involuntary intoxication </ins>of the <ins style="font-weight: bold; text-decoration: none;">SCRA ADB-BUTINACA after vaping. There are several pitfalls </ins>in the <ins style="font-weight: bold; text-decoration: none;">detection </ins>of <ins style="font-weight: bold; text-decoration: none;">SCRA in samples taken from the patient</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Data availabili</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at <ins style="font-weight: bold; text-decoration: none;">JWH-210 powder </ins>least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS represents a significant advancement </ins>in <ins style="font-weight: bold; text-decoration: none;">the field of drug detection, offering higher sensitivity, specificity, and </ins>a <ins style="font-weight: bold; text-decoration: none;">broader spectrum of detectable substances</ins>. <ins style="font-weight: bold; text-decoration: none;">Despite all negative results </ins>in the <ins style="font-weight: bold; text-decoration: none;">point-of</ins>-<ins style="font-weight: bold; text-decoration: none;">care test for recreational drugs</ins>, the <ins style="font-weight: bold; text-decoration: none;">liquid chromatography-quadrupole time</ins>-<ins style="font-weight: bold; text-decoration: none;">of</ins>-<ins style="font-weight: bold; text-decoration: none;">flight mass spectrometry </ins>(<ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS</ins>) <ins style="font-weight: bold; text-decoration: none;">analysis </ins>showed <ins style="font-weight: bold; text-decoration: none;">that the liquid </ins>of <ins style="font-weight: bold; text-decoration: none;">the e-cigarette contained ADB-BUTINACA</ins>, <ins style="font-weight: bold; text-decoration: none;">a synthetic cannabinoid</ins>. <ins style="font-weight: bold; text-decoration: none;">We report </ins>a <ins style="font-weight: bold; text-decoration: none;">27</ins>-<ins style="font-weight: bold; text-decoration: none;">year</ins>-<ins style="font-weight: bold; text-decoration: none;">old man who was admitted to </ins>the <ins style="font-weight: bold; text-decoration: none;">emergency room because of sudden JWH</ins>-210 <ins style="font-weight: bold; text-decoration: none;">powder headache</ins>, <ins style="font-weight: bold; text-decoration: none;">nausea</ins>, <ins style="font-weight: bold; text-decoration: none;">vertigo</ins>, <ins style="font-weight: bold; text-decoration: none;">red eyes </ins>and <ins style="font-weight: bold; text-decoration: none;">palpitations</ins>. <ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids are gaining popularity globally </ins>and <ins style="font-weight: bold; text-decoration: none;">detection </ins>is <ins style="font-weight: bold; text-decoration: none;">not commonly available</ins>.&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Data availability </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">When clinical presentation and/</ins>or <ins style="font-weight: bold; text-decoration: none;">initial DOA testing results are inconclusive</ins>, <ins style="font-weight: bold; text-decoration: none;">additional testing </ins>with <ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS can be valuable </ins>and <ins style="font-weight: bold; text-decoration: none;">is recommended</ins>. <ins style="font-weight: bold; text-decoration: none;">SCRAs </ins>and other <ins style="font-weight: bold; text-decoration: none;">NPS may not be detected by point</ins>-of-<ins style="font-weight: bold; text-decoration: none;">care DOA tests</ins>. <ins style="font-weight: bold; text-decoration: none;">In this case</ins>, <ins style="font-weight: bold; text-decoration: none;">the point</ins>-of-<ins style="font-weight: bold; text-decoration: none;">care DOA urine screening </ins>was <ins style="font-weight: bold; text-decoration: none;">not able </ins>to <ins style="font-weight: bold; text-decoration: none;">detect </ins>the <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoid ADB-BUTINAC</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225135&oldid=prev 2026-05-24T09:38:32Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:38, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">The same procedure was then applied </del>to <del style="font-weight: bold; text-decoration: none;">the mice once every day </del>for <del style="font-weight: bold; text-decoration: none;">5 days</del>. <del style="font-weight: bold; text-decoration: none;">It was considered as coordination disturbance when mice fell from </del>the <del style="font-weight: bold; text-decoration: none;">test apparatus within 2 min. Mice </del>that <del style="font-weight: bold; text-decoration: none;">remained their position </del>on the <del style="font-weight: bold; text-decoration: none;">running apparatus at 10 rpm for at least 2 min were selected for further evaluation</del>.<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Table </del>of <del style="font-weight: bold; text-decoration: none;">Conten</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Tremors were observed </del>in <del style="font-weight: bold; text-decoration: none;">mice 30 minutes following 1 mg/kg AMB</del>-<del style="font-weight: bold; text-decoration: none;">FUBINACA in the present study</del>. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. <del style="font-weight: bold; text-decoration: none;">Average potency </del>of the discriminative stimulus effects of <del style="font-weight: bold; text-decoration: none;">early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas </del>the <del style="font-weight: bold; text-decoration: none;">potency </del>of <del style="font-weight: bold; text-decoration: none;">a recent set was 0.09±0.03 mg/kg </del>(<del style="font-weight: bold; text-decoration: none;">Gatch et al</del>., <del style="font-weight: bold; text-decoration: none;">2018), and </del>the <del style="font-weight: bold; text-decoration: none;">potency </del>of the <del style="font-weight: bold; text-decoration: none;">current set is 0.05±0.01 mg/kg</del>. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier <del style="font-weight: bold; text-decoration: none;">compound</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Our findings revealed that both victims consumed large amounts </del>of <del style="font-weight: bold; text-decoration: none;">alcohol preceding their deaths (blood alcohol concentrations (BAC) </del>were <del style="font-weight: bold; text-decoration: none;">2</del>.<del style="font-weight: bold; text-decoration: none;">11 and 2.49 g/L, respectively). Forensic autopsy </del>of <del style="font-weight: bold; text-decoration: none;">both victims was performed four days after the time of death following the Recommendation No</del>.<del style="font-weight: bold; text-decoration: none;">R (99)3 of the Council of Europe on medico</del>-<del style="font-weight: bold; text-decoration: none;">legal autopsies. Elegans demonstrated </del>the <del style="font-weight: bold; text-decoration: none;">ability to form </del>all <del style="font-weight: bold; text-decoration: none;">of </del>the in-<del style="font-weight: bold; text-decoration: none;">vivo metabolites and has the potential to be used as a complementary model to predict and characterize human metabolites, as well as identifying possible drug toxicities for emerging SCBs</del>. <del style="font-weight: bold; text-decoration: none;">Thus, identification </del>of the <del style="font-weight: bold; text-decoration: none;">relevant urinary markers was based primarily upon the prevalence of the in</del>-<del style="font-weight: bold; text-decoration: none;">vivo metabolites instead of the metabolites ranking that was based upon % peak area abundance ratio. Moreover, genetic makeup, physiological conditions </del>(<del style="font-weight: bold; text-decoration: none;">age</del>, <del style="font-weight: bold; text-decoration: none;">gender 4F ADB and ethnicity), environmental influences (diet</del>) and <del style="font-weight: bold; text-decoration: none;">pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences </del>in <del style="font-weight: bold; text-decoration: none;">ionization capacity and matrix effects bias for each metabolite.&lt;br&gt;Data concerning </del>the <del style="font-weight: bold; text-decoration: none;">combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult </del>. <del style="font-weight: bold; text-decoration: none;">The threshold SCRA concentration for fatal overdose can be estimated ng</del>/<del style="font-weight: bold; text-decoration: none;">mL level </del>(<del style="font-weight: bold; text-decoration: none;">0</del>.<del style="font-weight: bold; text-decoration: none;">37–4</del>.<del style="font-weight: bold; text-decoration: none;">1 ng/mL according to the reported cases</del>) <del style="font-weight: bold; text-decoration: none;">in cases in </del>which <del style="font-weight: bold; text-decoration: none;">1.5–2.</del>5 <del style="font-weight: bold; text-decoration: none;">g/L of ethanol is present in the blood</del>. <del style="font-weight: bold; text-decoration: none;">The victims were brothers who were both found deceased </del>after <del style="font-weight: bold; text-decoration: none;">consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling </del>the <del style="font-weight: bold; text-decoration: none;">drugs to the public</del>. <del style="font-weight: bold; text-decoration: none;">Monitoring metabolism of synthetic cannabinoid 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">BINACA via </del>high-<del style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed </del>in <del style="font-weight: bold; text-decoration: none;">cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with </del>human <del style="font-weight: bold; text-decoration: none;">participants or animals performed by any of the author</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Product ions detected </del>at <del style="font-weight: bold; text-decoration: none;">m/z 302</del>, <del style="font-weight: bold; text-decoration: none;">217</del>, and <del style="font-weight: bold; text-decoration: none;">145 (B2) confirmed that tert-leucine </del>and <del style="font-weight: bold; text-decoration: none;">indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy</del>-<del style="font-weight: bold; text-decoration: none;">functional group at the 4</del>-<del style="font-weight: bold; text-decoration: none;">position </del>of <del style="font-weight: bold; text-decoration: none;">the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion</del>, <del style="font-weight: bold; text-decoration: none;">m/z 364 (B14</del>, <del style="font-weight: bold; text-decoration: none;">B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</del>. <del style="font-weight: bold; text-decoration: none;">The presence of the product ion m/z 320</del>, <del style="font-weight: bold; text-decoration: none;">likely formed from </del>a <del style="font-weight: bold; text-decoration: none;">loss of carbon dioxide</del>, <del style="font-weight: bold; text-decoration: none;">indicated monohydroxylation at the tert-leucine </del>in <del style="font-weight: bold; text-decoration: none;">B8 (m/z 219)</del>, <del style="font-weight: bold; text-decoration: none;">butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161)</del>. The <del style="font-weight: bold; text-decoration: none;">precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis </del>of <del style="font-weight: bold; text-decoration: none;">methyl ester from 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA</del>.&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Fig. 2. </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite </del>(<del style="font-weight: bold; text-decoration: none;">B22</del>). <del style="font-weight: bold; text-decoration: none;">Data obtained from the twenty urine </del>samples were <del style="font-weight: bold; text-decoration: none;">retrospectively analysed </del>and <del style="font-weight: bold; text-decoration: none;">processed using TraceFinder software based on the identification criteria of mass errors less than ± </del>5 <del style="font-weight: bold; text-decoration: none;">ppm for full MS peaks </del>and <del style="font-weight: bold; text-decoration: none;">MS/MS peaks from </del>the <del style="font-weight: bold; text-decoration: none;">theoretical mass and matching of MS/MS spectra</del>. <del style="font-weight: bold; text-decoration: none;">The mixture was vortex</del>-<del style="font-weight: bold; text-decoration: none;">mixed and 500 µL </del>of <del style="font-weight: bold; text-decoration: none;">this mixture </del>and <del style="font-weight: bold; text-decoration: none;">500 µL of methanol were loaded onto the Clean Screen FASt® tube</del>. <del style="font-weight: bold; text-decoration: none;">After incubation</del>, <del style="font-weight: bold; text-decoration: none;">the mixture was cooled at room temperature</del>, and <del style="font-weight: bold; text-decoration: none;">150 µL of purified water was added. High</del>-<del style="font-weight: bold; text-decoration: none;">resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated </del>in <del style="font-weight: bold; text-decoration: none;">both positive and negative ion modes, to determine accurate masses of the metabolites</del>. <del style="font-weight: bold; text-decoration: none;">Chromatographic separation was performed on an Agilent 1290 LC system with </del>a <del style="font-weight: bold; text-decoration: none;">Poroshell 120 EC-C18 </del>analytical <del style="font-weight: bold; text-decoration: none;">column (2.7 μm</del>, <del style="font-weight: bold; text-decoration: none;">75 × 2</del>.<del style="font-weight: bold; text-decoration: none;">1 mm; Agilent Technologies</del>, <del style="font-weight: bold; text-decoration: none;">Santa Clara</del>, <del style="font-weight: bold; text-decoration: none;">CA</del>, <del style="font-weight: bold; text-decoration: none;">USA)</del>.&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Fig. 1. </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Monitoring metabolism </del>of <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoid 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line</del>, <del style="font-weight: bold; text-decoration: none;">fungus</del>, <del style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb</del>.<del style="font-weight: bold; text-decoration: none;">com/ 4F ADB] liver microsomes and confirmed using urine samples </del>The <del style="font-weight: bold; text-decoration: none;">threshold </del>for <del style="font-weight: bold; text-decoration: none;">fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL </del>(<del style="font-weight: bold; text-decoration: none;">0</del>.<del style="font-weight: bold; text-decoration: none;">37–4.1 ng/mL according to the reported cases) </del>of <del style="font-weight: bold; text-decoration: none;">SCRA and </del>1<del style="font-weight: bold; text-decoration: none;">.5–2.5 g</del>/<del style="font-weight: bold; text-decoration: none;">L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol</del>, <del style="font-weight: bold; text-decoration: none;">because their combined use clearly increases their toxicity</del>. <del style="font-weight: bold; text-decoration: none;">The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission </del>. <del style="font-weight: bold; text-decoration: none;">Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29</del>, <del style="font-weight: bold; text-decoration: none;">30]</del>, <del style="font-weight: bold; text-decoration: none;">but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors</del>, <del style="font-weight: bold; text-decoration: none;">data on their simultaneous use may yield important insights in this regard</del>.<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Fungus C</del>. <del style="font-weight: bold; text-decoration: none;">elegans &lt;br&gt;Concentrations </del>of <del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA in </del>the <del style="font-weight: bold; text-decoration: none;">postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose </del>of <del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between </del>0.<del style="font-weight: bold; text-decoration: none;">10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease</del>, <del style="font-weight: bold; text-decoration: none;">the SCRA concentration in the postmortem blood was less than </del>1 <del style="font-weight: bold; text-decoration: none;">ng</del>/<del style="font-weight: bold; text-decoration: none;">mL </del>. <del style="font-weight: bold; text-decoration: none;">Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar </ins>to <ins style="font-weight: bold; text-decoration: none;">those adb butinaca of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted </ins>for <ins style="font-weight: bold; text-decoration: none;">Δ9-THC (Gamage et al., 2018)</ins>. <ins style="font-weight: bold; text-decoration: none;">The chemical structures of </ins>the <ins style="font-weight: bold; text-decoration: none;">recent synthetic cannabinoids are unlike </ins>that <ins style="font-weight: bold; text-decoration: none;">of Δ9-THC, but are largely based </ins>on the <ins style="font-weight: bold; text-decoration: none;">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014</ins>. <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA produced tremors and may be </ins>of <ins style="font-weight: bold; text-decoration: none;">increased risk in human recreational users.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Michael B Gatch </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">These findings are </ins>in <ins style="font-weight: bold; text-decoration: none;">agreement with earlier studies showing the synthetic cannabinoids substitute for the discriminative stimulus effects of Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC (see review by Wiley et al., 2017)</ins>. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. <ins style="font-weight: bold; text-decoration: none;">As mentioned previously, short-onset compounds have a greater abuse liability; further, compounds that have fewer adverse effects while they are active are likely to be preferred. All five of the compounds in the present study fully substituted with a pretreatment time of 15 min, suggesting a rapid onset </ins>of the discriminative stimulus effects<ins style="font-weight: bold; text-decoration: none;">. All </ins>of the <ins style="font-weight: bold; text-decoration: none;">cathinones fully substituted for the discriminative stimulus effects </ins>of <ins style="font-weight: bold; text-decoration: none;">Δ9-tetrahydrocannabinol </ins>(<ins style="font-weight: bold; text-decoration: none;">≥80% drug-appropriate responding)</ins>. <ins style="font-weight: bold; text-decoration: none;">Because response suppression may compromise stimulus control</ins>, <ins style="font-weight: bold; text-decoration: none;">rats failing to complete at least ten responses during the test session were excluded from </ins>the <ins style="font-weight: bold; text-decoration: none;">analysis </ins>of the <ins style="font-weight: bold; text-decoration: none;">discriminative stimulus effects of that dose of test compoun&lt;br&gt;&lt;br&gt;4</ins>. <ins style="font-weight: bold; text-decoration: none;">Drugs &lt;br&gt;</ins>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier <ins style="font-weight: bold; text-decoration: none;">compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&lt;br&gt;Michael B Gat</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Effects </ins>of <ins style="font-weight: bold; text-decoration: none;">individual doses </ins>were <ins style="font-weight: bold; text-decoration: none;">compared to the vehicle control value using a priori contrasts</ins>. <ins style="font-weight: bold; text-decoration: none;">Response-rate data were analyzed by one-way repeated-measure analysis </ins>of <ins style="font-weight: bold; text-decoration: none;">variance</ins>. <ins style="font-weight: bold; text-decoration: none;">Percent drug</ins>-<ins style="font-weight: bold; text-decoration: none;">appropriate responding was shown only if at adb butinaca least three rats completed </ins>the <ins style="font-weight: bold; text-decoration: none;">first fixed ratio, whereas </ins>all <ins style="font-weight: bold; text-decoration: none;">rats are shown for </ins>the <ins style="font-weight: bold; text-decoration: none;">response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate </ins>in <ins style="font-weight: bold; text-decoration: none;">a dose</ins>-<ins style="font-weight: bold; text-decoration: none;">dependent manner</ins>. <ins style="font-weight: bold; text-decoration: none;">A total </ins>of <ins style="font-weight: bold; text-decoration: none;">5 mice in </ins>the <ins style="font-weight: bold; text-decoration: none;">JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">081 </ins>(<ins style="font-weight: bold; text-decoration: none;">5 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">i.p.</ins>) <ins style="font-weight: bold; text-decoration: none;">treated group </ins>and <ins style="font-weight: bold; text-decoration: none;">6 mice </ins>in the <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f-adb</ins>.<ins style="font-weight: bold; text-decoration: none;">com</ins>/ <ins style="font-weight: bold; text-decoration: none;">adb butinaca] JWH-210 </ins>(<ins style="font-weight: bold; text-decoration: none;">5 mg/kg, i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.) <ins style="font-weight: bold; text-decoration: none;">treated group showed loss of traction, of </ins>which <ins style="font-weight: bold; text-decoration: none;">4 and </ins>5 <ins style="font-weight: bold; text-decoration: none;">showed tremor, respectively</ins>. <ins style="font-weight: bold; text-decoration: none;">Memory retention was measured </ins>after the <ins style="font-weight: bold; text-decoration: none;">memory acquisition was tested as a probe trial</ins>.<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt;About Powder JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">2&lt;br&gt;&lt;br&gt;The findings produce an apparent paradox, since CPP and self</ins>-<ins style="font-weight: bold; text-decoration: none;">administration predict with </ins>high <ins style="font-weight: bold; text-decoration: none;">reliability the likelihood that a compound will be abused by humans, and cannabinoids are well</ins>-<ins style="font-weight: bold; text-decoration: none;">known to produce active drug-seeking </ins>in human&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Buy Jwh-210 </ins>at <ins style="font-weight: bold; text-decoration: none;">USA K2 INCENSE STORE and enjoy premium quality</ins>, <ins style="font-weight: bold; text-decoration: none;">flexible quantities</ins>, and <ins style="font-weight: bold; text-decoration: none;">fast, secure shipping. Fast shipping </ins>and <ins style="font-weight: bold; text-decoration: none;">pure product</ins>-<ins style="font-weight: bold; text-decoration: none;">highly recommended for anyone needing quality incense ingredients." 🌟🌟🌟🌟🌟 You can buy jwh</ins>-<ins style="font-weight: bold; text-decoration: none;">210 online in quantities </ins>of <ins style="font-weight: bold; text-decoration: none;">adb butinaca 10g, 30g, 50g, 100g</ins>, <ins style="font-weight: bold; text-decoration: none;">150g</ins>, <ins style="font-weight: bold; text-decoration: none;">and 200g at USA K2 INCENSE STORE for premium quality and discreet shipping</ins>. <ins style="font-weight: bold; text-decoration: none;">In some areas</ins>, <ins style="font-weight: bold; text-decoration: none;">it is classified as </ins>a <ins style="font-weight: bold; text-decoration: none;">controlled substance</ins>, <ins style="font-weight: bold; text-decoration: none;">while </ins>in <ins style="font-weight: bold; text-decoration: none;">others</ins>, <ins style="font-weight: bold; text-decoration: none;">it may be legal for research or incense use</ins>. The <ins style="font-weight: bold; text-decoration: none;">legal status </ins>of <ins style="font-weight: bold; text-decoration: none;">jwh</ins>-<ins style="font-weight: bold; text-decoration: none;">210 varies by country and region</ins>.&lt;br&gt; <ins style="font-weight: bold; text-decoration: none;">Key Features and Specifications to Evaluate </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">In case of cannabis or Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">tetrahydrocannabinol, there are many adb butinaca previous studies regarding with their dependence potential and neurotoxicity </ins>(<ins style="font-weight: bold; text-decoration: none;">Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998</ins>). <ins style="font-weight: bold; text-decoration: none;">After administering test substances once every other day for 10 days, brain </ins>samples <ins style="font-weight: bold; text-decoration: none;">of mice </ins>were <ins style="font-weight: bold; text-decoration: none;">collected, especially at nucleus accumbens </ins>and <ins style="font-weight: bold; text-decoration: none;">hippocampus regions. Drug was administered </ins>5 <ins style="font-weight: bold; text-decoration: none;">times every other day, </ins>and the <ins style="font-weight: bold; text-decoration: none;">first trial was performed 2 h after the last administration</ins>.<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt; How to Choose Powder JWH-210 &lt;br&gt;This dual</ins>-<ins style="font-weight: bold; text-decoration: none;">use nature underscores the importance </ins>of <ins style="font-weight: bold; text-decoration: none;">responsible sourcing </ins>and <ins style="font-weight: bold; text-decoration: none;">strict adherence to legal frameworks</ins>. <ins style="font-weight: bold; text-decoration: none;">Forensic labs</ins>, <ins style="font-weight: bold; text-decoration: none;">public health researchers</ins>, and <ins style="font-weight: bold; text-decoration: none;">customs officials use authentic samples like JWH</ins>-<ins style="font-weight: bold; text-decoration: none;">210 to distinguish between legal and illegal compounds </ins>in <ins style="font-weight: bold; text-decoration: none;">seized materials</ins>. <ins style="font-weight: bold; text-decoration: none;">For those seeking </ins>a <ins style="font-weight: bold; text-decoration: none;">dependable compound for </ins>analytical <ins style="font-weight: bold; text-decoration: none;">purposes</ins>, <ins style="font-weight: bold; text-decoration: none;">JWH-210 Chemical Powder provides a trusted and effective solution</ins>. <ins style="font-weight: bold; text-decoration: none;">With its carefully controlled production process</ins>, <ins style="font-weight: bold; text-decoration: none;">stable composition</ins>, <ins style="font-weight: bold; text-decoration: none;">and secure packaging</ins>, <ins style="font-weight: bold; text-decoration: none;">it remains a valuable resource for laboratory-based research</ins>.&lt;br&gt; <ins style="font-weight: bold; text-decoration: none;">Is JWH-210 Legal? </ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">To evaluate whether the changes </ins>of <ins style="font-weight: bold; text-decoration: none;">coordinative functions by CNS damages were due to test substances, rota</ins>-<ins style="font-weight: bold; text-decoration: none;">rod test was performed using Rota</ins>-<ins style="font-weight: bold; text-decoration: none;">rod apparatus (Daejong</ins>, <ins style="font-weight: bold; text-decoration: none;">Seoul</ins>, <ins style="font-weight: bold; text-decoration: none;">Korea)</ins>. The <ins style="font-weight: bold; text-decoration: none;">test apparatus </ins>for <ins style="font-weight: bold; text-decoration: none;">the locomotor activity test was designed to measure locomotor activity automatically using UV system </ins>(<ins style="font-weight: bold; text-decoration: none;">AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in the chamber</ins>. <ins style="font-weight: bold; text-decoration: none;">In both tests, a group </ins>of <ins style="font-weight: bold; text-decoration: none;">mice were treated with negative control (vehicle, </ins>1 <ins style="font-weight: bold; text-decoration: none;">mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg</ins>, <ins style="font-weight: bold; text-decoration: none;">i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.<ins style="font-weight: bold; text-decoration: none;">)</ins>, <ins style="font-weight: bold; text-decoration: none;">positive control (methamphetamine</ins>, <ins style="font-weight: bold; text-decoration: none;">1 mg/kg</ins>, <ins style="font-weight: bold; text-decoration: none;">i</ins>.<ins style="font-weight: bold; text-decoration: none;">p</ins>.<ins style="font-weight: bold; text-decoration: none;">), or one </ins>of the <ins style="font-weight: bold; text-decoration: none;">three doses </ins>of <ins style="font-weight: bold; text-decoration: none;">test substances (</ins>0.<ins style="font-weight: bold; text-decoration: none;">1</ins>, 1<ins style="font-weight: bold; text-decoration: none;">, 5 mg</ins>/<ins style="font-weight: bold; text-decoration: none;">kg, i</ins>.<ins style="font-weight: bold; text-decoration: none;">p.) once every other day for 10 day</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225113&oldid=prev 2026-05-24T09:35:35Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:35, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Despite all negative results in </del>the <del style="font-weight: bold; text-decoration: none;">point-of-care test </del>for <del style="font-weight: bold; text-decoration: none;">recreational drugs, </del>the <del style="font-weight: bold; text-decoration: none;">liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed </del>that the <del style="font-weight: bold; text-decoration: none;">liquid </del>of <del style="font-weight: bold; text-decoration: none;">the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoi</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">A limitation </del>of <del style="font-weight: bold; text-decoration: none;">this case report is that we did not have a urine sample available for additional NPS testing</del>. <del style="font-weight: bold; text-decoration: none;">Point-</del>of<del style="font-weight: bold; text-decoration: none;">-care DOA tests using urine to screen for misuse </del>of <del style="font-weight: bold; text-decoration: none;">multiple substances</del>, <del style="font-weight: bold; text-decoration: none;">regularly include cannabis</del>, <del style="font-weight: bold; text-decoration: none;">amphetamines, cocaine, opioids, benzodiazepines and methadone</del>. <del style="font-weight: bold; text-decoration: none;">THC</del>, <del style="font-weight: bold; text-decoration: none;">methamphetamine, SRCA, lysergic acid diethylamide (LSD</del>), <del style="font-weight: bold; text-decoration: none;">gamma-hydroxybutyrate (GHB) </del>and <del style="font-weight: bold; text-decoration: none;">ketamine are likely to become volatile under </del>the <del style="font-weight: bold; text-decoration: none;">temperature </del>of current <del style="font-weight: bold; text-decoration: none;">e</del>-<del style="font-weight: bold; text-decoration: none;">cigarettes</del>, <del style="font-weight: bold; text-decoration: none;">while crack cocaine is hard to vaporise</del>. <del style="font-weight: bold; text-decoration: none;">A systematic review including data </del>of <del style="font-weight: bold; text-decoration: none;">114 patients </del>of <del style="font-weight: bold; text-decoration: none;">which </del>the <del style="font-weight: bold; text-decoration: none;">majority was intoxicated due </del>to <del style="font-weight: bold; text-decoration: none;">SCRA smoking revealed that 45 % </del>of <del style="font-weight: bold; text-decoration: none;">the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours</del>&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Figure 1. </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Each training session lasted a maximum </del>of <del style="font-weight: bold; text-decoration: none;">10 min</del>, <del style="font-weight: bold; text-decoration: none;">and </del>the <del style="font-weight: bold; text-decoration: none;">rats could earn up to 20 food pellets</del>. <del style="font-weight: bold; text-decoration: none;">Thirty minutes prior </del>to the <del style="font-weight: bold; text-decoration: none;">training sessions, rats received an injection of either vehicle or Δ9</del>-<del style="font-weight: bold; text-decoration: none;">THC </del>and <del style="font-weight: bold; text-decoration: none;">were subsequently placed in </del>the <del style="font-weight: bold; text-decoration: none;">behavior-testing chambers</del>, <del style="font-weight: bold; text-decoration: none;">where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available </del>as <del style="font-weight: bold; text-decoration: none;">a reinforcer </del>for <del style="font-weight: bold; text-decoration: none;">every ten responses (FR10) on a designated injection appropriate lever</del>. <del style="font-weight: bold; text-decoration: none;">A houselight </del>was <del style="font-weight: bold; text-decoration: none;">centered over </del>the <del style="font-weight: bold; text-decoration: none;">hopper close to </del>the <del style="font-weight: bold; text-decoration: none;">ceiling and was illuminated only when </del>the <del style="font-weight: bold; text-decoration: none;">levers were active. Each dose range included doses </del>that <del style="font-weight: bold; text-decoration: none;">were without effect to those producing at least 50</del>% <del style="font-weight: bold; text-decoration: none;">depression compared to vehicle control</del>. <del style="font-weight: bold; text-decoration: none;">Twenty-four male Sprague-Dawley rats were obtained from Envigo </del>(<del style="font-weight: bold; text-decoration: none;">Houston</del>, <del style="font-weight: bold; text-decoration: none;">TX</del>)<del style="font-weight: bold; text-decoration: none;">. Male ND4 Swiss–Webster mice were obtained from Envigo </del>(<del style="font-weight: bold; text-decoration: none;">Houston</del>, <del style="font-weight: bold; text-decoration: none;">TX</del>) <del style="font-weight: bold; text-decoration: none;">at approximately 8 weeks </del>of <del style="font-weight: bold; text-decoration: none;">age </del>and <del style="font-weight: bold; text-decoration: none;">maintained in the University of North Texas Health Science Center (UNTHSC) animal facility </del>for <del style="font-weight: bold; text-decoration: none;">two weeks prior to testin</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;&lt;br&gt;All </del>of <del style="font-weight: bold; text-decoration: none;">the compounds tested in the present study depressed locomotor activity as is typical </del>for <del style="font-weight: bold; text-decoration: none;">other synthetic cannabinoids </del>(<del style="font-weight: bold; text-decoration: none;">see review by Wiley et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2017)</del>. <del style="font-weight: bold; text-decoration: none;">Average horizontal activity counts</del>/<del style="font-weight: bold; text-decoration: none;">10 min as a function of time (10 min bins</del>) <del style="font-weight: bold; text-decoration: none;">and dose</del>. <del style="font-weight: bold; text-decoration: none;">Depressant effects </del>of <del style="font-weight: bold; text-decoration: none;">1</del>.<del style="font-weight: bold; text-decoration: none;">33 mg/kg </del>were <del style="font-weight: bold; text-decoration: none;">observed within 10 min following administration </del>and <del style="font-weight: bold; text-decoration: none;">peak depressant effects </del>were <del style="font-weight: bold; text-decoration: none;">JWH</del>-<del style="font-weight: bold; text-decoration: none;">210 powder observed between 0–30 min</del>. <del style="font-weight: bold; text-decoration: none;">Duration </del>of the <del style="font-weight: bold; text-decoration: none;">locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">After the incubation</del>, <del style="font-weight: bold; text-decoration: none;">mixture was centrifuged </del>(<del style="font-weight: bold; text-decoration: none;">18,000 x g, 20 °C</del>) <del style="font-weight: bold; text-decoration: none;">for 5 min </del>and <del style="font-weight: bold; text-decoration: none;">0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step</del>, <del style="font-weight: bold; text-decoration: none;">ammonium formate as salting agent was added </del>to the <del style="font-weight: bold; text-decoration: none;">mixture and incubated in </del>a <del style="font-weight: bold; text-decoration: none;">thermomixer (20 °C, 1200 rpm) for 15 min. After vortex</del>-<del style="font-weight: bold; text-decoration: none;">mixing, </del>the <del style="font-weight: bold; text-decoration: none;">mixture was allowed to stand [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb</del>.<del style="font-weight: bold; text-decoration: none;">com</del>/ <del style="font-weight: bold; text-decoration: none;">JWH-210 powder] at room temperature for 5 min</del>. <del style="font-weight: bold; text-decoration: none;">MS</del>/<del style="font-weight: bold; text-decoration: none;">MS experiments were performed in MRM </del>(<del style="font-weight: bold; text-decoration: none;">multiple reaction monitoring</del>) <del style="font-weight: bold; text-decoration: none;">mode with an isolation window </del>of <del style="font-weight: bold; text-decoration: none;">0.4 </del>m/z. The <del style="font-weight: bold; text-decoration: none;">MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates&lt;br&gt;&lt;br&gt;&lt;br&gt;The % peak area abundance ratio </del>of <del style="font-weight: bold; text-decoration: none;">metabolites detected in </del>the <del style="font-weight: bold; text-decoration: none;">urine samples are often affected by numerous factors such as drug intake behaviour (intake route</del>, <del style="font-weight: bold; text-decoration: none;">amount </del>of <del style="font-weight: bold; text-decoration: none;">drug and intake frequency)</del>, <del style="font-weight: bold; text-decoration: none;">time from last drug intake and metabolic stability. This </del>indicated <del style="font-weight: bold; text-decoration: none;">that </del>the <del style="font-weight: bold; text-decoration: none;">phase I metabolism of 4F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation </del>(<del style="font-weight: bold; text-decoration: none;">B17</del>) <del style="font-weight: bold; text-decoration: none;">metabolite</del>, <del style="font-weight: bold; text-decoration: none;">the second major metabolite after monohydroxylation </del>in the <del style="font-weight: bold; text-decoration: none;">C. Ester </del>hydrolysis <del style="font-weight: bold; text-decoration: none;">with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine </del>methyl ester <del style="font-weight: bold; text-decoration: none;">moieties such as 5F</del>-MDMB-<del style="font-weight: bold; text-decoration: none;">PINACA and </del>MDMB-<del style="font-weight: bold; text-decoration: none;">4en-PINACA [39, 40]. Similar to </del>the <del style="font-weight: bold; text-decoration: none;">in-vivo findings, </del>4F-MDMB-BINACA ester hydrolysis (B22) <del style="font-weight: bold; text-decoration: none;">was </del>the <del style="font-weight: bold; text-decoration: none;">major metabolite </del>for <del style="font-weight: bold; text-decoration: none;">both HepG2 </del>and <del style="font-weight: bold; text-decoration: none;">HLM models, consistent with </del>the <del style="font-weight: bold; text-decoration: none;">known hydrolytic activity </del>of <del style="font-weight: bold; text-decoration: none;">CES reported&lt;br&gt;&lt;br&gt;There is indication that at least some </del>of the <del style="font-weight: bold; text-decoration: none;">first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al</del>., <del style="font-weight: bold; text-decoration: none;">2016)</del>, and <del style="font-weight: bold; text-decoration: none;">a compound from the present study, 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB</del>-<del style="font-weight: bold; text-decoration: none;">PINACA</del>, was <del style="font-weight: bold; text-decoration: none;">found to activate midbrain dopamine neurons, but not serotonin neurons </del>(<del style="font-weight: bold; text-decoration: none;">Asaoka et al</del>., <del style="font-weight: bold; text-decoration: none;">2016</del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;4</del>. <del style="font-weight: bold; text-decoration: none;">Drugs </del>&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">Short</del>-<del style="font-weight: bold; text-decoration: none;">onset</del>, <del style="font-weight: bold; text-decoration: none;">short</del>-<del style="font-weight: bold; text-decoration: none;">acting compounds have </del>a <del style="font-weight: bold; text-decoration: none;">greater abuse liability, </del>and <del style="font-weight: bold; text-decoration: none;">long-acting compounds pose problems </del>of <del style="font-weight: bold; text-decoration: none;">long-acting adverse effects and interactions with other drugs</del>. The <del style="font-weight: bold; text-decoration: none;">duration of action </del>of the <del style="font-weight: bold; text-decoration: none;">synthetic cannabinoids tested using the 8</del>-<del style="font-weight: bold; text-decoration: none;">h protocol </del>have <del style="font-weight: bold; text-decoration: none;">varied widely</del>, <del style="font-weight: bold; text-decoration: none;">with some producing a duration of action </del>no <del style="font-weight: bold; text-decoration: none;">longer than 1 h, others producing a duration </del>of <del style="font-weight: bold; text-decoration: none;">action between 1–2 h</del>, <del style="font-weight: bold; text-decoration: none;">and others lasting more than 2 h</del>. <del style="font-weight: bold; text-decoration: none;">There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds</del>. <del style="font-weight: bold; text-decoration: none;">All </del>of the <del style="font-weight: bold; text-decoration: none;">compounds tested </del>in the <del style="font-weight: bold; text-decoration: none;">present study depressed locomotor activity as </del>is <del style="font-weight: bold; text-decoration: none;">typical for other synthetic cannabinoids (see review by Wiley et al.</del>, <del style="font-weight: bold; text-decoration: none;">2017)</del>. <del style="font-weight: bold; text-decoration: none;">Average horizontal activity counts/10 min as a function of time (</del>10 <del style="font-weight: bold; text-decoration: none;">min bins) </del>and <del style="font-weight: bold; text-decoration: none;">dose</del>. <del style="font-weight: bold; text-decoration: none;">Depressant effects of </del>1<del style="font-weight: bold; text-decoration: none;">.33 mg</del>/<del style="font-weight: bold; text-decoration: none;">kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min</del>.<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;Michael B Gat</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">The same procedure was then applied to </ins>the <ins style="font-weight: bold; text-decoration: none;">mice once every day </ins>for <ins style="font-weight: bold; text-decoration: none;">5 days. It was considered as coordination disturbance when mice fell from </ins>the <ins style="font-weight: bold; text-decoration: none;">test apparatus within 2 min. Mice </ins>that <ins style="font-weight: bold; text-decoration: none;">remained their position on </ins>the <ins style="font-weight: bold; text-decoration: none;">running apparatus at 10 rpm for at least 2 min were selected for further evaluation.&lt;br&gt;Table </ins>of <ins style="font-weight: bold; text-decoration: none;">Conten</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time </ins>of <ins style="font-weight: bold; text-decoration: none;">peak depression in the locomotor activity assay in mice</ins>. <ins style="font-weight: bold; text-decoration: none;">Average potency </ins>of <ins style="font-weight: bold; text-decoration: none;">the discriminative stimulus effects </ins>of <ins style="font-weight: bold; text-decoration: none;">early compounds was 0.81±0.17 mg/kg (Gatch et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2014)</ins>, <ins style="font-weight: bold; text-decoration: none;">whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al</ins>., <ins style="font-weight: bold; text-decoration: none;">2018</ins>), and the <ins style="font-weight: bold; text-decoration: none;">potency </ins>of <ins style="font-weight: bold; text-decoration: none;">the </ins>current <ins style="font-weight: bold; text-decoration: none;">set is 0.05±0.01 mg/kg. Short</ins>-<ins style="font-weight: bold; text-decoration: none;">onset</ins>, <ins style="font-weight: bold; text-decoration: none;">short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs</ins>. <ins style="font-weight: bold; text-decoration: none;">The duration </ins>of <ins style="font-weight: bold; text-decoration: none;">action </ins>of the <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems </ins>to <ins style="font-weight: bold; text-decoration: none;">be a trend </ins>of <ins style="font-weight: bold; text-decoration: none;">newer synthetic cannabinoids being more potent than earlier compound</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Our findings revealed that both victims consumed large amounts </ins>of <ins style="font-weight: bold; text-decoration: none;">alcohol preceding their deaths (blood alcohol concentrations (BAC) were 2.11 and 2.49 g/L</ins>, <ins style="font-weight: bold; text-decoration: none;">respectively). Forensic autopsy of both victims was performed four days after the time of death following the Recommendation No.R (99)3 of </ins>the <ins style="font-weight: bold; text-decoration: none;">Council of Europe on medico-legal autopsies</ins>. <ins style="font-weight: bold; text-decoration: none;">Elegans demonstrated the ability </ins>to <ins style="font-weight: bold; text-decoration: none;">form all of </ins>the <ins style="font-weight: bold; text-decoration: none;">in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites </ins>and <ins style="font-weight: bold; text-decoration: none;">has </ins>the <ins style="font-weight: bold; text-decoration: none;">potential to be used as a complementary model to predict and characterize human metabolites</ins>, as <ins style="font-weight: bold; text-decoration: none;">well as identifying possible drug toxicities </ins>for <ins style="font-weight: bold; text-decoration: none;">emerging SCBs</ins>. <ins style="font-weight: bold; text-decoration: none;">Thus, identification of the relevant urinary markers </ins>was <ins style="font-weight: bold; text-decoration: none;">based primarily upon </ins>the <ins style="font-weight: bold; text-decoration: none;">prevalence of </ins>the <ins style="font-weight: bold; text-decoration: none;">in-vivo metabolites instead of </ins>the <ins style="font-weight: bold; text-decoration: none;">metabolites ranking </ins>that <ins style="font-weight: bold; text-decoration: none;">was based upon </ins>% <ins style="font-weight: bold; text-decoration: none;">peak area abundance ratio</ins>. <ins style="font-weight: bold; text-decoration: none;">Moreover, genetic makeup, physiological conditions </ins>(<ins style="font-weight: bold; text-decoration: none;">age, gender 4F ADB and ethnicity)</ins>, <ins style="font-weight: bold; text-decoration: none;">environmental influences (diet</ins>) <ins style="font-weight: bold; text-decoration: none;">and pathological factors </ins>(<ins style="font-weight: bold; text-decoration: none;">liver diseases, diabetes</ins>, <ins style="font-weight: bold; text-decoration: none;">and obesity</ins>) <ins style="font-weight: bold; text-decoration: none;">would further complicate the metabolism </ins>of <ins style="font-weight: bold; text-decoration: none;">drugs. It should be noted that % peak area abundance ratios do not necessarily reflect absolute concentrations due to differences in ionization capacity </ins>and <ins style="font-weight: bold; text-decoration: none;">matrix effects bias </ins>for <ins style="font-weight: bold; text-decoration: none;">each metabolite.</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation </ins>of <ins style="font-weight: bold; text-decoration: none;">possible overdose cases difficult . The threshold SCRA concentration </ins>for <ins style="font-weight: bold; text-decoration: none;">fatal overdose can be estimated ng/mL level </ins>(<ins style="font-weight: bold; text-decoration: none;">0</ins>.<ins style="font-weight: bold; text-decoration: none;">37–4</ins>.<ins style="font-weight: bold; text-decoration: none;">1 ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL according to the reported cases</ins>) <ins style="font-weight: bold; text-decoration: none;">in cases in which 1.5–2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 g/L </ins>of <ins style="font-weight: bold; text-decoration: none;">ethanol is present in the blood</ins>. <ins style="font-weight: bold; text-decoration: none;">The victims were brothers who </ins>were <ins style="font-weight: bold; text-decoration: none;">both found deceased after consuming 4F-MDMB-BINACA </ins>and <ins style="font-weight: bold; text-decoration: none;">ethanol. These confusing shorter names were not scientifically adopted but </ins>were <ins style="font-weight: bold; text-decoration: none;">used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples</ins>. <ins style="font-weight: bold; text-decoration: none;">This article does not contain any studies with human participants or animals performed by any </ins>of the <ins style="font-weight: bold; text-decoration: none;">author</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Product ions detected at m/z 302, 217</ins>, <ins style="font-weight: bold; text-decoration: none;">and 145 </ins>(<ins style="font-weight: bold; text-decoration: none;">B2</ins>) <ins style="font-weight: bold; text-decoration: none;">confirmed that tert-leucine </ins>and <ins style="font-weight: bold; text-decoration: none;">indazole moieties remained unchanged</ins>, <ins style="font-weight: bold; text-decoration: none;">leading </ins>to the <ins style="font-weight: bold; text-decoration: none;">structure elucidation of </ins>a <ins style="font-weight: bold; text-decoration: none;">hydroxy</ins>-<ins style="font-weight: bold; text-decoration: none;">functional group at </ins>the <ins style="font-weight: bold; text-decoration: none;">4</ins>-<ins style="font-weight: bold; text-decoration: none;">position of the butyl side chain by oxidative defluorination</ins>. <ins style="font-weight: bold; text-decoration: none;">The product ion m</ins>/<ins style="font-weight: bold; text-decoration: none;">z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites</ins>. <ins style="font-weight: bold; text-decoration: none;">The precursor ion, m</ins>/<ins style="font-weight: bold; text-decoration: none;">z 364 </ins>(<ins style="font-weight: bold; text-decoration: none;">B14, B5/B6</ins>) <ins style="font-weight: bold; text-decoration: none;">had a loss </ins>of <ins style="font-weight: bold; text-decoration: none;">2 Da from </ins>m/z <ins style="font-weight: bold; text-decoration: none;">366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</ins>. The <ins style="font-weight: bold; text-decoration: none;">presence </ins>of the <ins style="font-weight: bold; text-decoration: none;">product ion m/z 320</ins>, <ins style="font-weight: bold; text-decoration: none;">likely formed from a loss </ins>of <ins style="font-weight: bold; text-decoration: none;">carbon dioxide</ins>, indicated <ins style="font-weight: bold; text-decoration: none;">monohydroxylation at </ins>the <ins style="font-weight: bold; text-decoration: none;">tert</ins>-<ins style="font-weight: bold; text-decoration: none;">leucine in B8 </ins>(<ins style="font-weight: bold; text-decoration: none;">m/z 219</ins>), <ins style="font-weight: bold; text-decoration: none;">butyl side chain in B9 (m/z 145) and indazole moiety </ins>in <ins style="font-weight: bold; text-decoration: none;">B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining </ins>the hydrolysis <ins style="font-weight: bold; text-decoration: none;">of </ins>methyl ester <ins style="font-weight: bold; text-decoration: none;">from 4F</ins>-MDMB-<ins style="font-weight: bold; text-decoration: none;">BINACA.&lt;br&gt;Fig. 2. &lt;br&gt;4F-</ins>MDMB-<ins style="font-weight: bold; text-decoration: none;">BINACA was hydrolysed via ester hydrolysis forming </ins>the 4F-MDMB-BINACA ester hydrolysis <ins style="font-weight: bold; text-decoration: none;">metabolite </ins>(B22)<ins style="font-weight: bold; text-decoration: none;">. Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on </ins>the <ins style="font-weight: bold; text-decoration: none;">identification criteria of mass errors less than ± 5 ppm </ins>for <ins style="font-weight: bold; text-decoration: none;">full MS peaks </ins>and <ins style="font-weight: bold; text-decoration: none;">MS/MS peaks from </ins>the <ins style="font-weight: bold; text-decoration: none;">theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL </ins>of <ins style="font-weight: bold; text-decoration: none;">this mixture and 500 µL </ins>of <ins style="font-weight: bold; text-decoration: none;">methanol were loaded onto </ins>the <ins style="font-weight: bold; text-decoration: none;">Clean Screen FASt® tube</ins>. <ins style="font-weight: bold; text-decoration: none;">After incubation</ins>, <ins style="font-weight: bold; text-decoration: none;">the mixture was cooled at room temperature</ins>, and <ins style="font-weight: bold; text-decoration: none;">150 µL of purified water was added. High</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution QTOF</ins>-<ins style="font-weight: bold; text-decoration: none;">MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes</ins>, <ins style="font-weight: bold; text-decoration: none;">to determine accurate masses of the metabolites. Chromatographic separation </ins>was <ins style="font-weight: bold; text-decoration: none;">performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column </ins>(<ins style="font-weight: bold; text-decoration: none;">2</ins>.<ins style="font-weight: bold; text-decoration: none;">7 μm</ins>, <ins style="font-weight: bold; text-decoration: none;">75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).</ins>&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Fig. 1</ins>. &lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high</ins>-<ins style="font-weight: bold; text-decoration: none;">resolution mass spectrometry assessed in cultured hepatoma cell line, fungus</ins>, <ins style="font-weight: bold; text-decoration: none;">[https://cannabinoidsrc4f</ins>-<ins style="font-weight: bold; text-decoration: none;">adb.com/ 4F ADB] liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as </ins>a <ins style="font-weight: bold; text-decoration: none;">little ng/mL (0.37–4.1 ng/mL according to the reported cases) of SCRA </ins>and <ins style="font-weight: bold; text-decoration: none;">1.5–2.5 g/L </ins>of <ins style="font-weight: bold; text-decoration: none;">ethanol</ins>. The <ins style="font-weight: bold; text-decoration: none;">reported cases and reviews </ins>of the <ins style="font-weight: bold; text-decoration: none;">scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi</ins>-<ins style="font-weight: bold; text-decoration: none;">organ failure 11 days after hospital admission . Studies </ins>have <ins style="font-weight: bold; text-decoration: none;">found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30]</ins>, <ins style="font-weight: bold; text-decoration: none;">but </ins>no <ins style="font-weight: bold; text-decoration: none;">data on high doses </ins>of <ins style="font-weight: bold; text-decoration: none;">ethanol are available. Given that THC and ethanol act on the same receptors</ins>, <ins style="font-weight: bold; text-decoration: none;">data on their simultaneous use may yield important insights in this regard</ins>.<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt;Fungus C</ins>. <ins style="font-weight: bold; text-decoration: none;">elegans &lt;br&gt;Concentrations </ins>of <ins style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA in </ins>the <ins style="font-weight: bold; text-decoration: none;">postmortem blood samples were 2.50 and 2.34 ng/mL, which are </ins>in <ins style="font-weight: bold; text-decoration: none;">line with published data. Although </ins>the <ins style="font-weight: bold; text-decoration: none;">lethal dose of 4F-MDMB-BINACA </ins>is <ins style="font-weight: bold; text-decoration: none;">unknown</ins>, <ins style="font-weight: bold; text-decoration: none;">its concentration in postmortem blood samples was found to range between 0</ins>.10 and <ins style="font-weight: bold; text-decoration: none;">2.90 ng/mL </ins>. <ins style="font-weight: bold; text-decoration: none;">In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than </ins>1 <ins style="font-weight: bold; text-decoration: none;">ng</ins>/<ins style="font-weight: bold; text-decoration: none;">mL </ins>. <ins style="font-weight: bold; text-decoration: none;">Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20</ins></div></td></tr> </table>

Norris9662 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225058&oldid=prev 2026-05-24T09:28:57Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:28, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those adb butinaca of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.&lt;br&gt;Michael B Gatch &lt;br&gt;Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA </del>in <del style="font-weight: bold; text-decoration: none;">3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH&lt;br&gt;&lt;br&gt;&lt;br&gt;High resolution mass spectrometry such as LC-QTOF-MS allows </del>the <del style="font-weight: bold; text-decoration: none;">detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A </del>point-of-care <del style="font-weight: bold; text-decoration: none;">drugs of abuse (DOA) </del>test <del style="font-weight: bold; text-decoration: none;">was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time </del>for <del style="font-weight: bold; text-decoration: none;">both chromatograms</del>, <del style="font-weight: bold; text-decoration: none;">demonstrating the [https://cannabinoidsrc4f-adb.com/ adb butinaca] presence and elution profiles of nicotine and ADB-BUTINACA in </del>the <del style="font-weight: bold; text-decoration: none;">analysed vape </del>liquid <del style="font-weight: bold; text-decoration: none;">sample. LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS Chromatograms </del>of <del style="font-weight: bold; text-decoration: none;">Nicotine (Top) and ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA </del>(<del style="font-weight: bold; text-decoration: none;">Bottom) in the Vape Liquid used by the patient. The </del>LC-QTOF-MS analysis showed that the e-<del style="font-weight: bold; text-decoration: none;">liquid </del>contained <del style="font-weight: bold; text-decoration: none;">nicotine and </del>ADB-BUTINACA <del style="font-weight: bold; text-decoration: none;">(Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances</del>, <del style="font-weight: bold; text-decoration: none;">the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating </del>a <del style="font-weight: bold; text-decoration: none;">light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del style="font-weight: bold; text-decoration: none;">LC separates the </del>urine <del style="font-weight: bold; text-decoration: none;">or blood </del>sample <del style="font-weight: bold; text-decoration: none;">and QTOF-MS provides high-resolution and accurate mass measurements </del>for <del style="font-weight: bold; text-decoration: none;">precise identification and structural elucidation of compounds</del>. <del style="font-weight: bold; text-decoration: none;">The LC</del>-<del style="font-weight: bold; text-decoration: none;">QTOF</del>-<del style="font-weight: bold; text-decoration: none;">MS method offers a more comprehensive and sensitive approach </del>for <del style="font-weight: bold; text-decoration: none;">drug detection</del>, <del style="font-weight: bold; text-decoration: none;">covering hundreds of recreational drugs</del>, <del style="font-weight: bold; text-decoration: none;">including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability</del>, <del style="font-weight: bold; text-decoration: none;">one can elevate the flow rate of air through the e-cigarette </del>and<del style="font-weight: bold; text-decoration: none;">/or add a diluent </del>. <del style="font-weight: bold; text-decoration: none;">Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong</del>, <del style="font-weight: bold; text-decoration: none;">together with synthetic opioids</del>, <del style="font-weight: bold; text-decoration: none;">cathinones</del>, <del style="font-weight: bold; text-decoration: none;">amphetamines and hallucinogens to the new psychoactive substances </del>(<del style="font-weight: bold; text-decoration: none;">NPS</del>) <del style="font-weight: bold; text-decoration: none;">that are currently developed at high speed.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;There is indication that at least some of the first</del>-<del style="font-weight: bold; text-decoration: none;">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </del>(<del style="font-weight: bold; text-decoration: none;">Wiley et al., 2016</del>)<del style="font-weight: bold; text-decoration: none;">, </del>and <del style="font-weight: bold; text-decoration: none;">a compound from </del>the <del style="font-weight: bold; text-decoration: none;">present study, 5F</del>-<del style="font-weight: bold; text-decoration: none;">MDMB-PINACA</del>, <del style="font-weight: bold; text-decoration: none;">was found </del>to <del style="font-weight: bold; text-decoration: none;">activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al</del>.<del style="font-weight: bold; text-decoration: none;">, 2016&lt;br&gt;&lt;br&gt;&lt;br&gt;This might be due to the low activity </del>of <del style="font-weight: bold; text-decoration: none;">numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite </del>of <del style="font-weight: bold; text-decoration: none;">4F-MDMB-BINACA in abundance but </del>the <del style="font-weight: bold; text-decoration: none;">rest </del>of the <del style="font-weight: bold; text-decoration: none;">metabolites were found in a small amount. Elegans and HLM models detected all of </del>the <del style="font-weight: bold; text-decoration: none;">in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl</del>&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Despite all negative results </ins>in the point-of-care test for <ins style="font-weight: bold; text-decoration: none;">recreational drugs</ins>, the liquid <ins style="font-weight: bold; text-decoration: none;">chromatography</ins>-<ins style="font-weight: bold; text-decoration: none;">quadrupole time</ins>-of-<ins style="font-weight: bold; text-decoration: none;">flight mass spectrometry </ins>(LC-QTOF-MS<ins style="font-weight: bold; text-decoration: none;">) </ins>analysis showed that <ins style="font-weight: bold; text-decoration: none;">the liquid of </ins>the e-<ins style="font-weight: bold; text-decoration: none;">cigarette </ins>contained ADB-BUTINACA, a <ins style="font-weight: bold; text-decoration: none;">synthetic cannabinoi</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">A limitation of this case report is that we did not have a </ins>urine sample <ins style="font-weight: bold; text-decoration: none;">available </ins>for <ins style="font-weight: bold; text-decoration: none;">additional NPS testing</ins>. <ins style="font-weight: bold; text-decoration: none;">Point</ins>-<ins style="font-weight: bold; text-decoration: none;">of</ins>-<ins style="font-weight: bold; text-decoration: none;">care DOA tests using urine to screen </ins>for <ins style="font-weight: bold; text-decoration: none;">misuse of multiple substances, regularly include cannabis, amphetamines</ins>, <ins style="font-weight: bold; text-decoration: none;">cocaine</ins>, <ins style="font-weight: bold; text-decoration: none;">opioids</ins>, <ins style="font-weight: bold; text-decoration: none;">benzodiazepines </ins>and <ins style="font-weight: bold; text-decoration: none;">methadone</ins>. <ins style="font-weight: bold; text-decoration: none;">THC</ins>, <ins style="font-weight: bold; text-decoration: none;">methamphetamine</ins>, <ins style="font-weight: bold; text-decoration: none;">SRCA</ins>, <ins style="font-weight: bold; text-decoration: none;">lysergic acid diethylamide </ins>(<ins style="font-weight: bold; text-decoration: none;">LSD</ins>)<ins style="font-weight: bold; text-decoration: none;">, gamma</ins>-<ins style="font-weight: bold; text-decoration: none;">hydroxybutyrate </ins>(<ins style="font-weight: bold; text-decoration: none;">GHB</ins>) and <ins style="font-weight: bold; text-decoration: none;">ketamine are likely to become volatile under </ins>the <ins style="font-weight: bold; text-decoration: none;">temperature of current e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarettes</ins>, <ins style="font-weight: bold; text-decoration: none;">while crack cocaine is hard </ins>to <ins style="font-weight: bold; text-decoration: none;">vaporise</ins>. <ins style="font-weight: bold; text-decoration: none;">A systematic review including data </ins>of <ins style="font-weight: bold; text-decoration: none;">114 patients </ins>of <ins style="font-weight: bold; text-decoration: none;">which </ins>the <ins style="font-weight: bold; text-decoration: none;">majority was intoxicated due to SCRA smoking revealed that 45 % </ins>of the <ins style="font-weight: bold; text-decoration: none;">patients who present at </ins>the <ins style="font-weight: bold; text-decoration: none;">ER after an intoxication due to SCRA smoking recovered within 24 hours</ins>&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<ins style="font-weight: bold; text-decoration: none;">&lt;br&gt;&lt;br&gt;&lt;br&gt;All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were JWH-210 powder observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k&lt;br&gt;&lt;br&gt;&lt;br&gt;After the incubation, mixture was centrifuged (18,000 x g, 20 °C) for 5 min and 0.5 μL of the supernatant was directly injected to the chromatographic system. In the next step, ammonium formate as salting agent was added to the mixture and incubated in a thermomixer (20 °C, 1200 rpm) for 15 min. After vortex-mixing, the mixture was allowed to stand [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] at room temperature for 5 min. MS/MS experiments were performed in MRM (multiple reaction monitoring) mode with an isolation window of 0.4 m/z. The MS measurement was performed in positive ion mode (except for some acidic compounds such as barbiturates&lt;br&gt;&lt;br&gt;&lt;br&gt;The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major metabolite after monohydroxylation in the C. Ester hydrolysis with dehydrogenation formed in-vivo in this study was also reported among other indazole carboxamide type SCBs with tert-leucine methyl ester moieties such as 5F-MDMB-PINACA and MDMB-4en-PINACA [39, 40]. Similar to the in-vivo findings, 4F-MDMB-BINACA ester hydrolysis (B22) was the major metabolite for both HepG2 and HLM models, consistent with the known hydrolytic activity of CES reported&lt;br&gt;&lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.&lt;br&gt;Michael B Gat</ins></div></td></tr> </table>

DamonAngas210 https://whdc.ac/index.php?title=4FADB,4F-ADB,&diff=225044&oldid=prev 2026-05-24T09:27:20Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:27, 24 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">To evaluate whether the changes </del>of <del style="font-weight: bold; text-decoration: none;">coordinative functions by CNS damages were due to test substances</del>, <del style="font-weight: bold; text-decoration: none;">rota</del>-<del style="font-weight: bold; text-decoration: none;">rod test was performed using Rota</del>-<del style="font-weight: bold; text-decoration: none;">rod apparatus </del>(<del style="font-weight: bold; text-decoration: none;">Daejong</del>, <del style="font-weight: bold; text-decoration: none;">Seoul, Korea</del>). The <del style="font-weight: bold; text-decoration: none;">test apparatus for </del>the locomotor activity <del style="font-weight: bold; text-decoration: none;">test was designed </del>to <del style="font-weight: bold; text-decoration: none;">measure locomotor activity automatically using UV system (AM 1051</del>, <del style="font-weight: bold; text-decoration: none;">Benwick Electronics, Benwick, UK) when experimental animals moved </del>in the <del style="font-weight: bold; text-decoration: none;">chamber</del>. <del style="font-weight: bold; text-decoration: none;">In both tests, a group of mice were treated with negative control (vehicle, </del>1 mg/kg<del style="font-weight: bold; text-decoration: none;">, i</del>.<del style="font-weight: bold; text-decoration: none;">p</del>.<del style="font-weight: bold; text-decoration: none;">), positive control (methamphetamine</del>, 1 mg/kg, <del style="font-weight: bold; text-decoration: none;">i</del>.<del style="font-weight: bold; text-decoration: none;">p.), or one of </del>the <del style="font-weight: bold; text-decoration: none;">three doses of test substances </del>(0.<del style="font-weight: bold; text-decoration: none;">1, 1, </del>5 mg/kg<del style="font-weight: bold; text-decoration: none;">, i.p</del>.) <del style="font-weight: bold; text-decoration: none;">once every other day for 10 day</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;LC-QTOF-MS <del style="font-weight: bold; text-decoration: none;">represents </del>a <del style="font-weight: bold; text-decoration: none;">significant advancement in </del>the <del style="font-weight: bold; text-decoration: none;">field </del>of <del style="font-weight: bold; text-decoration: none;">drug detection</del>, <del style="font-weight: bold; text-decoration: none;">offering higher sensitivity</del>, <del style="font-weight: bold; text-decoration: none;">specificity</del>, and <del style="font-weight: bold; text-decoration: none;">a broader spectrum </del>of <del style="font-weight: bold; text-decoration: none;">detectable substances</del>. <del style="font-weight: bold; text-decoration: none;">Despite all negative results </del>in the point-of-care test <del style="font-weight: bold; text-decoration: none;">for </del>recreational <del style="font-weight: bold; text-decoration: none;">drugs</del>, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <del style="font-weight: bold; text-decoration: none;">analysis showed that </del>the <del style="font-weight: bold; text-decoration: none;">liquid </del>of the e-cigarette <del style="font-weight: bold; text-decoration: none;">contained ADB</del>-<del style="font-weight: bold; text-decoration: none;">BUTINACA</del>, <del style="font-weight: bold; text-decoration: none;">a </del>synthetic cannabinoid. <del style="font-weight: bold; text-decoration: none;">We report </del>a <del style="font-weight: bold; text-decoration: none;">27</del>-<del style="font-weight: bold; text-decoration: none;">year</del>-<del style="font-weight: bold; text-decoration: none;">old man who </del>was <del style="font-weight: bold; text-decoration: none;">admitted </del>to the <del style="font-weight: bold; text-decoration: none;">emergency room because </del>of <del style="font-weight: bold; text-decoration: none;">sudden [https://cannabinoidsrc4f</del>-<del style="font-weight: bold; text-decoration: none;">adb</del>.<del style="font-weight: bold; text-decoration: none;">com/ Jwh</del>-<del style="font-weight: bold; text-decoration: none;">210 Powder] headache</del>, <del style="font-weight: bold; text-decoration: none;">nausea</del>, <del style="font-weight: bold; text-decoration: none;">vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection </del>is <del style="font-weight: bold; text-decoration: none;">not commonly </del>availabl&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<del style="font-weight: bold; text-decoration: none;">&lt;br&gt;&lt;br&gt;&lt;br&gt;In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation. Known for its stability and consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc&lt;br&gt;&lt;br&gt;&lt;br&gt;Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound&lt;br&gt;&lt;br&gt;4. Drugs &lt;br&gt;The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in humans. Drug discrimination is a well-known animal model of the subjective effects of drugs and correlates well with abuse liability (Young 2009; Horton et al. 2013). Assessment of abuse liability is based on several factors, including chemical structure, pharmacological mechanism of action, and finally, subjective and reinforcing behavioral effects (FDA, 2010; Swedberg, 2013).&lt;br&gt;Michael B Gat</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those adb butinaca </ins>of <ins style="font-weight: bold; text-decoration: none;">Δ9-THC (Bannister and Connor, 2018)</ins>, <ins style="font-weight: bold; text-decoration: none;">and MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">FUBINACA fully substituted for Δ9</ins>-<ins style="font-weight: bold; text-decoration: none;">THC </ins>(<ins style="font-weight: bold; text-decoration: none;">Gamage et al.</ins>, <ins style="font-weight: bold; text-decoration: none;">2018</ins>). The <ins style="font-weight: bold; text-decoration: none;">chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on </ins>the <ins style="font-weight: bold; text-decoration: none;">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased </ins>locomotor activity <ins style="font-weight: bold; text-decoration: none;">and produced discriminative stimulus effects similar </ins>to <ins style="font-weight: bold; text-decoration: none;">those of Δ9-THC</ins>, <ins style="font-weight: bold; text-decoration: none;">which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk </ins>in <ins style="font-weight: bold; text-decoration: none;">human recreational users.&lt;br&gt;Michael B Gatch &lt;br&gt;Duration of </ins>the <ins style="font-weight: bold; text-decoration: none;">locomotor depression increased over dose from 30 min following 0</ins>.1 mg/kg <ins style="font-weight: bold; text-decoration: none;">to 2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 h following 1 mg/kg</ins>. <ins style="font-weight: bold; text-decoration: none;">Substantial depressant effects were observed within the first 10 min</ins>, <ins style="font-weight: bold; text-decoration: none;">and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following </ins>1 mg/kg <ins style="font-weight: bold; text-decoration: none;">AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min</ins>, <ins style="font-weight: bold; text-decoration: none;">and maximal depression was observed between 10–40 min and lasted up to 2</ins>.<ins style="font-weight: bold; text-decoration: none;">5 to 3 h at </ins>the <ins style="font-weight: bold; text-decoration: none;">highest dose tested </ins>(0.5 mg/kg<ins style="font-weight: bold; text-decoration: none;">)</ins>. <ins style="font-weight: bold; text-decoration: none;">Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h</ins>) <ins style="font-weight: bold; text-decoration: none;">and dose of Δ9-TH</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins style="font-weight: bold; text-decoration: none;">High resolution mass spectrometry such as </ins>LC-QTOF-MS <ins style="font-weight: bold; text-decoration: none;">allows the detection and identification of </ins>a <ins style="font-weight: bold; text-decoration: none;">broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on </ins>the <ins style="font-weight: bold; text-decoration: none;">urine </ins>of <ins style="font-weight: bold; text-decoration: none;">the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep</ins>, <ins style="font-weight: bold; text-decoration: none;">Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific</ins>, <ins style="font-weight: bold; text-decoration: none;">transient symptoms</ins>, <ins style="font-weight: bold; text-decoration: none;">clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the [https://cannabinoidsrc4f-adb.com/ adb butinaca] presence </ins>and <ins style="font-weight: bold; text-decoration: none;">elution profiles </ins>of <ins style="font-weight: bold; text-decoration: none;">nicotine and ADB-BUTINACA in the analysed vape liquid sample</ins>. <ins style="font-weight: bold; text-decoration: none;">LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) </ins>in <ins style="font-weight: bold; text-decoration: none;">the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because </ins>the point-of-care <ins style="font-weight: bold; text-decoration: none;">DOA </ins>test <ins style="font-weight: bold; text-decoration: none;">is generally not able to detect synthetic </ins>recreational <ins style="font-weight: bold; text-decoration: none;">drug substances</ins>, the <ins style="font-weight: bold; text-decoration: none;">liquid of the e-cigarette was thereafter screened using </ins>liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <ins style="font-weight: bold; text-decoration: none;">on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom&lt;br&gt;&lt;br&gt;&lt;br&gt;LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate </ins>the <ins style="font-weight: bold; text-decoration: none;">flow rate </ins>of <ins style="font-weight: bold; text-decoration: none;">air through </ins>the e-cigarette <ins style="font-weight: bold; text-decoration: none;">and/or add a diluent . Of all e</ins>-<ins style="font-weight: bold; text-decoration: none;">cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones</ins>, <ins style="font-weight: bold; text-decoration: none;">amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;There is indication that at least some of the first-generation </ins>synthetic <ins style="font-weight: bold; text-decoration: none;">cannabinoids act at receptors other than </ins>cannabinoid <ins style="font-weight: bold; text-decoration: none;">CB1 and CB2 (Wiley et al</ins>.<ins style="font-weight: bold; text-decoration: none;">, 2016), and </ins>a <ins style="font-weight: bold; text-decoration: none;">compound from the present study, 5F</ins>-<ins style="font-weight: bold; text-decoration: none;">MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">PINACA, </ins>was <ins style="font-weight: bold; text-decoration: none;">found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&lt;br&gt;&lt;br&gt;&lt;br&gt;This might be due </ins>to the <ins style="font-weight: bold; text-decoration: none;">low activity </ins>of <ins style="font-weight: bold; text-decoration: none;">numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB</ins>-<ins style="font-weight: bold; text-decoration: none;">BINACA in abundance but the rest of the metabolites were found in a small amount</ins>. <ins style="font-weight: bold; text-decoration: none;">Elegans and HLM models detected all of the in</ins>-<ins style="font-weight: bold; text-decoration: none;">vivo metabolites (100%)</ins>, <ins style="font-weight: bold; text-decoration: none;">whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence</ins>, <ins style="font-weight: bold; text-decoration: none;">structural elucidation could not be confirmed unless a reference standard </ins>is <ins style="font-weight: bold; text-decoration: none;">made </ins>availabl&lt;br&gt;&lt;br&gt;Figure 1. &lt;br&gt;Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin</div></td></tr> </table>

DamonAngas210